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Shan Xiao
BAYESIAN DESIGN AND ANALYSIS OF CLUSTER RANDOMIZED TRIALS
Cluster randomization is frequently used in clinical trials for convenience of inter-
ventional implementation and for reducing the risk of contamination. The opera-
tional convenience of cluster randomized trials, however, is gained at the expense
of reduced analytical power. Compared to individually randomized studies, cluster
randomized trials often have a much-reduced power. In this dissertation, I consider
ways of enhancing analytical power with historical trial data. Specifically, I introduce
a hierarchical Bayesian model that is designed to incorporate available information
from previous trials of the same or similar interventions. Operationally, the amount
of information gained from the previous trials is determined by a Kullback-Leibler
divergence measure that quantifies the similarity, or lack thereof, between the histor-
ical and current trial data. More weight is given to the historical data if they more
closely resemble the current trial data. Along this line, I examine the Type I error
rates and analytical power associated with the proposed method, in comparison with
the existing methods without utilizing the ancillary historical information. Similarly,
to design a cluster randomized trial, one could estimate the power by simulating trial
data and comparing them with the historical data from the published studies. Data
analytical and power simulation methods are developed for more general situations
of cluster randomized trials, with multiple arms and multiple types of data following
the exponential family of distributions. An R package is developed for practical use
of the methods in data analysis and trial design.
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Chapter 1
Introduction
1.1 Background of the Research
Cluster randomization is widely used in clinical trials. The design allows for testing
of interventional efficacy by comparing outcomes of individuals randomized by prede-
fined subject clusters or groups (Campbell, 2000; Campbell et al., 2007). In practice,
these clusters could be communities, families, or clinics. With this design, clusters
participating in a trial are randomly assigned to different treatment arms, and all
subjects within each cluster receive the same treatment. Trial outcomes are typically
assessed at the subject level, as in individual randomized trials.
Trialists usually choose the cluster randomized design for practical reasons
(Donner, 1998), such as convenience of implementation, or minimization of contam-
ination, etc. The design is particularly popular in situations where the intervention
is delivered at the cluster level. For example, in trials of electronic care reminders,
it is usually more practical to deliver the same reminder message to all patients in a
clinic, as opposed to sending different messages to different patients, or withholding
messages from randomly selected patients. In such situations, individual randomiza-
tion creates not only logistic and implementational difficulties, but also a potential
to contaminate the treatment effect through interactions among patients within the
same clinic.
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But the practical appeal of cluster randomization is retained at the expense
of a much reduced analytical power. In a typical two-arm cluster randomized trials
with k clusters per treatment arm and m subjects per cluster (i.e., a total of nC = km
subjects per arm), for example, one would need VIF= [1 + (m − 1)ρ] times of the
sample size of an individual randomized trial to detect an effect of the same magnitude
at the same power and level of significance (Hemming et al., 2011). Here ρ indicates
the intra-cluster correlation (ICC) coefficient, and VIF stands for Variance Inflation
Factor. As a result, in situations where there are relatively few large clusters with a
strong ICC, the inflation of sample size from individual randomized trials could be
severe, leading to a great reduction in analytical power.
How to improve analytical power in cluster randomized trials, therefore, be-
comes a question of great practical importance. In this proposal, we present a class
of Bayesian methods for the design and analysis of cluster randomized trials. The
proposed methods enhance the analytical power of cluster randomized trials by bor-
rowing strength from historical data.
1.2 Enhancing Power with Historical Data
The idea of borrowing information from historical data is not new. Using information
from previous trials of similar interventions to boost the power of the current trial
is intuitively an appealing idea (Viele et al., 2014). After all, efficacies of many
interventions are established through repeated testing in multiple trials, in different
patient populations and clinical settings, and through different delivery methods.
Philosophically, such an approach is no different from meta analysis, which
seeks to quantify an unknown treatment effect by combining all existing trials on the
2
same or similar interventions (Donner and Klar, 2002; Donner et al., 2001). While
people continue to debate the perceived fault of ignoring the inherent heterogeneity
among the historical trials, few challenge the notion that data from multiple studies
could be combined to achieve an improved treatment effect estimate (Darlington
and Donner, 2007; Donner et al., 2003; Laopaiboon, 2003; Shuster et al., 2007). In
fact, systematic review and meta analysis are generally regarded as at the top of the
hierarchy of scientific evidence (Guyatt et al., 1995).
Alternatively, one could approach the problem from the perspective of hierar-
chical Bayes, by formulating the prior distributions based on historical data (Clark
and Bachmann, 2010; Spiegelhalter, 2001; Turner et al., 2001). Specifically, a fre-
quently used method is to determine the prior parameters from historical data (Good-
man and Sladky, 2005; Hampson et al., 2014; Hobbs and Carlin, 2007; Schoenfeld
et al., 2009; Turner et al., 2005). To prevent an overwhelming influence of the his-
torical data, several researchers developed the idea of “discounting” the historical
information. Magnitude of the discount is quantified by a power parameter associ-
ated with the prior density, and thus leading to the concept of power prior (Duan,
2005; Ibrahim et al., 2015; Zhang, 2010).
1.3 An Overview of the Dissertation Research
An essential question concerning the use of prior trial data is how to determine the
relevance of historical information. For simplicity of the discussion, we assume that
those previous studies are on the same intervention. But having the same intervention
does not automatically give the historical data the same weight as the current trial
data, because the designer of the current trial has no control of the target populations,
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the settings, and the conduct of the previous trials. In other words, findings from
the previous studies are not necessarily generalizable to the current population and
clinical setting.
In the absence of a generally accepted mechanism for determination of the
similarity or dissimilarity between the current and historical trials, a reasonable ap-
proach is to adopt a data-driven method that directly evaluates the resemblance of
the distributions of the data sources. A greater resemblance indicates a stronger
affinity between the historical and current trials. A lower resemblance, on the other
hands, conveys a sense of dissimilarity.
In this dissertation, we propose to use the Kullback-Leibler (KL) divergence
measure to quantify the distance between the current and historical data, and then
use this distance measure to determine the amount of discounting of historical data.
A greater KL distance indicates a bigger discrepancy, and thus giving us less incentive
to place great weight on the historical information. To implement, we propose to use
the KL distance as the discounting parameter in a likelihood framework.
Our research has three separate but related pieces: (1) Bayesian Analysis of
data from cluster randomized trials; (2) Design of cluster randomized trials with
historical data; and (3) Development of computational tools for the data analysis and
trial design.
The methods that we present in this dissertation are Bayesian in the sense
that they use Bayesian techniques for incorporation of the historical data. The basic
clinical trial concepts, such as type I error rate and power, however, are still within the
frequentist trial framework. As we shall describe in greater details, such a merge of the
Bayesian and frequentist views offers an enhanced modeling flexibility, especially when
4
it comes to the incorporation of extraneous historical trial information, but at the
same time, it retains the more familiar frequentist trial concepts and interpretations.
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Chapter 2
Analysis of Two-arm Cluster Randomized Trials with Binary Outcome
2.1 Bayesian Power Priors
For a given trial, all information provided by previous studies are ancillary in nature.
One way to incorporate such information is through the use of power priors (Ibrahim
et al., 2015). Bayesian power prior has been studied by multiple authors (Chen et al.,
2006, 2000, 1998; De Santis, 2006, 2007; Duan et al., 2006; Ibrahim and Chen, 2000;
Matteucci and Veldkamp, 2015; Rietbergen et al., 2011; Shao, 2012). To the best of
my knowledge, however, it has not been used in cluster randomized trials. In this
work, we briefly review and describe how power priors are used to bring prior trial
data into the analysis. We start the discussion by considering the simplest situation
of one historical study.
We write the current data as D and historical data as D0. We additionally
assume that the likelihood functions based on the current and historical data are
L(θ|D) and L(θ|D0), respectively, where θ is the parameter of interest. With a
being a discounting parameter, the power prior of θ is constructed as follows,
pi(θ|D0, a) ∝ L(θ|D0)api0(θ), (2.1)
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where pi0(θ) is the original prior before the historical data D0 are made available. In
practice, pi0(θ) is typically chosen to be a non-informative probability density function
with heavier tails.
The discounting parameter a takes a value between 0 and 1. When a = 0, the
prior (2.1) degenerates to pi0(θ), which means all information in the historical data
is discounted and no ancillary information is incorporated in the prior specification;
when a = 1, (2.1) represents a distribution generated by updating pi0(θ) with the full
historical information through the Bayes theorem, implying no historical data will be
discounted. In general, the discounting fraction a controls the levels of influence of
historical data in the prior distribution formulation. Technically, parameter a controls
the shape of the power prior function (2.1). As a becomes smaller, the tails of the
power prior become heavier.
The basic formulation of the power prior is easily extendable to situations of
multiple historical data sources. Suppose there are J datasets from historical studies,
D1, . . . ,DJ , each of which corresponds to a unique discounting factor a1, . . . , aJ , the
power prior can therefore be expressed as
pi(θ|D1, . . . , DJ , a1, . . . , aJ) ∝ pi0(θ)
J∏
j=1
L(θ|Dj)aj . (2.2)
For simplicity of the narration, we shall limit the discussion to the situation of one
historical data, knowing that the method is easily extendable to situations where
multiple historical data sources are available.
The power prior in Equation (2.1) can be updated with the current data like-
lihood L(θ|D) via the Bayes theorem, resulting in a posterior of θ in the following
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form,
pi(θ|D,D0, a) ∝ L(θ|D)pi(θ|D0, a) ∝ L(θ|D)L(θ|D0)api0(θ). (2.3)
One could use posterior (2.3) to estimate θ, and perform inference.
It should be noted that Equation (2.1) assumes that the parameter of interest
is identical across all trials (Ibrahim and Chen, 2000). Such an assumption can be
relaxed by allowing the main parameter of interest to differ across trials, as long as
it follows a distribution that depends only on a common set of parameters from the
historical trials (Hobbs et al., 2011, 2012). An alternative way of accommodating
varying parameters is to assume the parameters are exchangeable in the current and
historical trials (Carlin, 1992). Such an assumption is frequently used in Bayesian
meta analysis, but rarely used in Bayesian power prior analysis.
2.2 Determination of Discounting Parameters
An essential step to incorporate the previous trial data is determining an appropriate
value for the discounting parameter a. One of the common methods is to subjectively
determine the value of a; the practice is usually based on expert opinions (De Santis,
2007; Rietbergen et al., 2011; Shao, 2012). To implement, analysts often try different
values between 0 and 1, and report results to content experts. The final decisions
are based on certain pre-specified criteria, such as the marginal likelihood criterion
(MLC) and deviance information criterion (DIC) (Ibrahim et al., 2015). Alterna-
tively, one could treat a as a random variable, and specify a hyper-prior to describe
its behavior, which is usually described by a non-informative distribution or a dis-
tribution driven by a commensurability parameter (Brian, 2010; Hobbs et al., 2011;
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Ibrahim et al., 2015). This latter approach is conceptually more attractive as the
discounting fraction is essentially data-driven. A downside of the approach is that it
often requires extensive computation.
Suppose that we have a two-arm cluster randomized trial with a binary out-
come, and the historical data come from a two-arm randomized trial on a similar
outcome. The historical trial is not necessarily cluster randomized, and its data may
come in a summarized fashion.
For the current trial, we assume the numbers of clusters in the control and
treatment arms to be I0 and I1, respectively. So the total number of clusters is
I = I0 + I1. Let Ji be the number of subjects in the ith cluster and Yij be the binary
outcome for the jth subject in the ith cluster. Yij takes the value 1 if the event
of interest is observed and 0 otherwise. Treatment assignment of the ith cluster is
indicated by X1i. The current trial data are therefore written as D = {(Yij, X1i), i =
1, 2, . . . , I, j = 1, 2, . . . , Ji}.
For the historical study, we let l be the treatment group indicator, with l = 0
indicating the control arm and l = 1 the treatment arm. Assuming that the data
come in a summarized form, and that Nl indicates the total number of subjects in
arm l, we let Zl be the number of events of interest observed in the lth arm and let
X2l be the treatment assignment. Then the historical data can be summarized as
D0 = {(Zl, Nl, X2l) : l = 0, 1}.
To determine the discounting fraction a, we propose the following models for
D and D0, which can be fitted separately (Congdon, 2007). Specifically, for the
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current data D, we assume Yij ∼ Bernoulli(pi), and
logit(pi) = β0 + β1X1i + bi, i = 1, 2, . . . , I, j = 1, 2, . . . , Ji, (2.4)
where bi ∼ N(0, τb), β0 ∼ N(µβ0 , τβ0), β1 ∼ N(µβ1 , τβ1), τb ∼ Gamma(κb, νb), and
β1 represents the treatment effects under D. For the simplicity of narration, we
denote b = (b1, b2, . . . , bI)
T . Similarly, for the historical data D0, we assume Zl ∼
Binomial(Nl, ql), and
logit(ql) = β
′
0 + β
′
1X
′
1l, l = 0, 1, (2.5)
where β′0 ∼ N(µβ′0 , τβ′0), β′1 ∼ N(µβ′1 , τβ′1) and β′1 stands for the treatment effect under
D0.
All priors for parameters in models (2.4) and (2.5) are assumed to be non-
informative. In separate data analyses, the posterior of β1 and β
′
1, denoted by f(β1|D)
and g(β′1|D0), are evaluated.
Since the two posteriors are derived under non-informative priors, they are not
influenced by external data other than the current and historical trial information.
From this, we ascertain the symmetric and asymmetric KL divergence measures, and
use them to quantify the similarity of the two data sources.
DsymKL (f ||g) = Ef{log(
f
g
)}+ Eg{log( g
f
)}, (2.6)
DasymKL (f ||g) = Ef{log(
f
g
)}, (2.7)
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where f and g stand for f(β1|D) and g(β′1|D0), and Ef{·} and Eg{·} are the expec-
tations taken with respect to f and g, respectively.
Under such a setup, we propose the following discounting fractions
asym = e−D
sym
KL (f ||g) = e−D
sym
KL (g||f). (2.8)
aasym = e−D
asym
KL (f ||g), (2.9)
The two KL divergence measures are not easy to compute by definition, we therefore
use the k-Nearest Neighbor (k-NN) algorithm for calculation.
2.3 Estimation of Treatment Effect
We assume β1 = (β1, β
′
1) follows a bivariate normal distribution with mean vector
m1 and precision matrix Λ1. Assuming β1 and β
′
1 are exchangeable, we could write
m1 = µ1(1, 1)
′, and Λ1 = τ1
 1 ρ1
ρ1 1

−1
. To complete the model specification, we
further assume µ1, τ1 and ρ1 follow the hyper-prior distributions as below,
h1(µ1|a1, R1) =
√
R1
2pi
e−
R1
2
(µ1−a1)2 ,
h1(τ1|κ1, ν1) = ν
κ1
1
Γ(κ1)
τκ1−11 e
−ν1τ1 , (2.10)
h1(ρ1|c1, d1) = ρ
c1−1
1 (1− ρ1)d1−1
B(c1, d1)
,
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where Γ(·) and B(·, ·) are respectively Gamma and Beta functions. The power prior
of β1 can therefore be written as
h(β1|D0, a) ∝
∫∫∫∫
{
∫
(L(β′0, β
′
1|D0))ag(β′0) dβ′0}h(β1, β′1|µ1, τ1, ρ1)
h(µ1|a1, R1)h(τ1|κ1, ν1)h(ρ1|c1, d1) dβ′1 dµ1 dτ1 dρ1,
(2.11)
where L(β′0, β
′
1|D0) and g(β′0) are the likelihood and prior density functions of β′0 and
β′1 in Model (2.5). From (2.11), we derive the posterior function of β1 as
h(β1|D,D0, a) ∝ {
∫
· · ·
∫
L(β0, β1|D, b)f(b|τb)f(β0)f(τb) db dβ0 dτb}h(β1|D0, a),
(2.12)
where L(β0, β1|D, b), f(β0),f(τb) and f(b|τb) are the (conditional) likelihood and
(prior) density functions of β0, β1, τb and b in Model (2.4).
Since the three posteriors f(β1|D), g(β′1|D0), h(β1|D,D0, a) do not have
closed forms, we use a Metropolis Hastings (MH) algorithm within Gibbs sampling
to draw samples from the posteriors. Treatment effect estimates are then obtained
from the appropriate summary statistics of the posterior samples.
2.4 Algorithms
2.4.1 The K-Nearest Neighbor Algorithm
To estimate the symmetric and asymmetric KL divergence (2.7) and (2.6) with the
posterior samples of β1 from f(β1|D) and β′1 from g(β′1|D0), people usually obtain
the histograms of equally sized bins with the posterior samples and then use these
histograms to estimate the posterior densities f and g and substitute the density
12
estimates fˆ and gˆ into equations (2.7) and (2.6). But this method is extensive in
computation, and the estimation accuracy deteriorates quickly as the dimension of
the densities f and g increases. To solve, an estimator of the KL divergence with
the nearest neighbor method has been proposed (Wang et al., 2009). This estimator
demonstrates asymptotically unbiased and mean-square consistent properties when
the posterior sample size is large enough. In this dissertation, the k-Nearest Neighbor
(k-NN) algorithm is applied to the posterior samples to yield this estimator, where
k is any constant since different k do not affect the two aforementioned properties
but the convergence rate of the k-NN algorithm. The R package ‘FNN’ (Beygelzimer
et al., 2013) is used to complete the computations. For the purpose of illustration,
the application of the k-NN algorithm in this dissertation is briefly introduced.
Let {β(1)1 , β(2)1 , . . . , β(n)1 } and {β′1(1), β′1(2), . . . , β′1(m)} be the posterior samples
of β1 from f(β1|D) and β′1 from g(β′1|D0), respectively. Let ρk(i) be the Euclidean
distance between β
(i)
1 and its k-NN in {β(j)1 }j 6=i. Specifically, the k-NN of x in
{z1, z2, . . . , zn} is zi(k) where i(1), i(2), . . . , i(n) is such that
||x− zi(1)|| ≤ ||x− zi(2)|| ≤ · · · ≤ ||x− zi(n)||.
The distance from β
(i)
1 to its k-NN in {β′1(1), β′1(2), . . . , β′1(m)} is denoted by νk(i), then
the asymmetric KL divergence DasymKL (f ||g) can be calculated as
DˆasymKL (f ||g) =
1
n
n∑
i=1
log(
νk(i)
ρk(i)
) + log(
m
n− 1), (2.13)
Similarly, let κk(j) be the Euclidean distance between β
′
1
(j) and its k-NN in {β′1(i)}i 6=j,
and the Euclidean distance from β′1
(j) to its k-NN in {β(1)1 , β(2)1 , . . . , β(n)1 } is denoted
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by λk(j), then the symmetric KL divergence D
sym
KL (f ||g) can be calculated as
DˆsymKL (f ||g) =
1
n
n∑
i=1
log(
νk(i)
ρk(i)
) + log(
m
n− 1) +
1
m
m∑
j=1
log(
λk(j)
κk(j)
) + log(
n
m− 1). (2.14)
Consequently, the symmetric and asymmetric discounting fraction could be
estimated as
aˆsym = e−Dˆ
sym
KL (f ||g) = e−Dˆ
sym
KL (g||f).
aˆasym = e−Dˆ
asym
KL (f ||g),
2.4.2 The Metropolis Hastings within Gibbs Algorithm
Markov Chain Monte Carlo (MCMC) method has been proposed to draw posterior
samples from a posterior distribution (Robert and Casella, 2009) when the poste-
rior distribution does not have a closed form. It is built upon two basic algorithms,
i.e. Gibbs algorithm and MH algorithm. These two algorithms have been extended
and modified in different ways for solving different problems (Chib and Carlin, 1999;
Gamerman, 1997). Many user-friendly statistical softwares have been well developed
to implement MCMC procedure, such as OpenBUGS (Lunn et al., 2009). The devel-
opment of the softwares makes MCMC easy to implement and helps it gain popularity
in Bayesian computation. To draw posterior samples from f(β1|D), g(β′1|D0) and
h(β1|D,D0, a), we propose a MH within Gibbs algorithm, and we develop both R
and OpenBUGS programs to run this algorithm.
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The Gibbs Component of the Hybrid Algorithm
We fit the current data D with Model (2.4) to draw posterior samples of β1 from the
posterior f(β1|D). The joint posterior of β1, β0, b and τb is
f(β1, β0, b, τb|D) = f(β1, β0, b, τb,D)
f(D)
=
f(Y |β1, β0, b)f(β1)f(β0)f(b|τb)f(τb)∫ ·· · ∫ f(Y |β1, β0, b)f(β1)f(β0)f(b|τb)f(τb) dβ1 dβ0 db dτb
∝ f(Y |β1, β0, b)f(β1)f(β0)f(b|τb)f(τb)
=
{
I∏
i=1
Ji∏
j=1
(
eβ0+β1X1i+bi
1 + eβ0+β1X1i+bi
)Yij(1− e
β0+β1X1i+bi
1 + eβ0+β1X1i+bi
)1−Yij
}
{√
τβ1
2pi
e−
τβ1
2
(β1−µβ1 )2
}{√
τβ0
2pi
e−
τβ0
2
(β0−µβ0 )2
}{ I∏
i=1
√
τb
2pi
e−
1
2
b2i τb
}{
νκbb
Γ(κb)
τκb−1b e
−νbτb
}
∝
{
I∏
i=1
Ji∏
j=1
(
eβ0+β1X1i+bi
1 + eβ0+β1X1i+bi
)Yij(1− e
β0+β1X1i+bi
1 + eβ0+β1X1i+bi
)1−Yij
}
{
e−
τβ
2
(β−µβ)2
}{
e−
τβ0
2
(β0−µβ0 )2
}{ I∏
i=1
√
τbe
− 1
2
b2i τb
}{
τκb−1b e
−νbτb} ,
where Y = (Y11, . . . , Y1J1 , . . . , YI1, . . . , YIJI ), b = (b1, . . . , bI). So the full conditionals
of β1, β0, b and τb are
f(β1|D, β0, b, τb) = f(β1|D, β0, b)
=
f(β1, β0, b, τb|D)
f(β0, b, τb|D)
=
f(β1, β0, b, τb|D)∫
f(β1, β0, b, τb|D) dβ1
=
{∏I
i=1
∏Ji
j=1(
eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)Yij(1− eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)1−Yij
}{
e−
τβ1
2
(β1−µβ1 )2
}
∫ {∏I
i=1
∏Ji
j=1(
eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)Yij(1− eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)1−Yij
}{
e−
τβ1
2
(β1−µβ1 )2
}
dβ1
∝
{
I∏
i=1
Ji∏
j=1
(
eβ0+β1X1i+bi
1 + eβ0+β1X1i+bi
)Yij(1− e
β0+β1X1i+bi
1 + eβ0+β1X1i+bi
)1−Yij
}{
e−
τβ1
2
(β1−µβ1 )2
}
,
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f(β0|D, β1, b, τb) = f(β0|D, β1, b)
=
f(β1, β0, b, τb|D)
f(β1, b, τb|D)
=
f(β1, β0, b, τb|D)∫
f(β1, β0, b, τb|D) dβ0
=
{∏I
i=1
∏Ji
j=1(
eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)Yij(1− eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)1−Yij
}{
e−
τβ0
2
(β0−µβ0 )2
}
∫ {∏I
i=1
∏Ji
j=1(
eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)Yij(1− eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)1−Yij
}{
e−
τβ0
2
(β0−µβ0 )2
}
dβ0
∝
{
I∏
i=1
Ji∏
j=1
(
eβ0+β1X1i+bi
1 + eβ0+β1X1i+bi
)Yij(1− e
β0+β1X1i+bi
1 + eβ0+β1X1i+bi
)1−Yij
}{
e−
τβ0
2
(β0−µβ0 )2
}
,
f(b|D, β1, β0, τb) = f(β1, β0, b, τb|D)
f(β1, β0, τb|D)
=
f(β1, β0, b, τb|D)∫ ·· · ∫ f(β1, β0, b, τb|D) db
=
{∏Ji
j=1(
eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)Yij(1− eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)1−Yij
}{∏I
i=1
√
τbe
− 1
2
b2i τb
}
∫ {∏Ji
j=1(
eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)Yij(1− eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)1−Yij
}{∏I
i=1
√
τbe
− 1
2
b2i τb
}
db
∝
{
Ji∏
j=1
(
eβ0+β1X1i+bi
1 + eβ0+β1X1i+bi
)Yij(1− e
β0+β1X1i+bi
1 + eβ0+β1X1i+bi
)1−Yij
}{
I∏
i=1
√
τbe
− 1
2
b2i τb
}
,
f(τb|D, β1, β0, b) = f(τb|b)
=
f(β1, β0, b, τb|D)
f(β1, β0, b|D)
=
f(β1, β0, b, τb|D)∫
f(β1, β0, b, τb|D) dτb
=
{∏I
i=1
√
τbe
− 1
2
b2i τb
}{
τκb−1b e
−νbτb}∫ {∏I
i=1
√
τbe
− 1
2
b2i τb
}{
τκb−1b e−νbτb
}
dτb
∝
{
I∏
i=1
√
τbe
− 1
2
b2i τb
}{
τκb−1b e
−νbτb}
∼ Gamma(κb + I
2
, νb +
∑I
i b
2
i
2
).
Secondly, we fit the historical data D0 with Model (2.5) to draw posterior
samples of β′1 from the posterior g(β
′
1|D0). The joint posterior of β′1 and β′0 is
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g(β′1, β
′
0|D0) =
g(β′1, β
′
0,D0)
g(D0)
=
g(Z|β′1, β′0)g(β′1)g(β′0)∫∫
g(Z|β′1, β′0)g(β′1)g(β′0) dβ′1 dβ′0
∝ g(Z|β′1, β′0)g(β′1)g(β′0)
=
{
1∏
l=0
(
eβ
′
0+β
′
1X
′
1l
1 + eβ
′
0+β
′
1X
′
1l
)Zl(1− e
β′0+β
′
1X
′
1l
1 + eβ
′
0+β
′
1X
′
1l
)Nl−Zl
}{√
τβ′1
2pi
e
−
τ
β′1
2
(β′1−µβ′1 )
2
}
{√
τβ′0
2pi
e
−
τ
β′0
2
(β′0−µβ′0 )
2
}
∝
{
1∏
l=0
(
eβ
′
0+β
′
1X
′
1l
1 + eβ
′
0+β
′
1X
′
1l
)Zl(1− e
β′0+β
′
1X
′
1l
1 + eβ
′
0+β
′
1X
′
1l
)Nl−Zl
}{
e
−
τ
β′1
2
(β′1−µβ′1 )
2
}
{
e
−
τ
β′0
2
(β′0−µβ′0 )
2
}
,
where Z = (Z0, Z1). So the full conditionals of β
′
1 and β
′
0 are
g(β′1|D0, β′0) =
g(β′1, β
′
0|D0)
g(β′0|D0)
=
g(β′1, β
′
0|D0)∫
g(β′1, β
′
0|D0) dβ′1
=
{∏1
l=0(
eβ
′
0+β
′
1X
′
1l
1+e
β′0+β′1X′1l
)Zl(1− eβ
′
0+β
′
1X
′
1l
1+e
β′0+β′1X′1l
)Nl−Zl
}{
e
−
τ
β′1
2
(β′1−µβ′1 )
2
}
∫ {∏1
l=0(
e
β′0+β′1X′1l
1+e
β′0+β′1X′1l
)Zl(1− eβ
′
0+β
′
1X
′
1l
1+e
β′0+β′1X′1l
)Nl−Zl
}{
e
−
τ
β′1
2
(β′1−µβ′1 )
2
}
dβ′1
∝
{
1∏
l=0
(
eβ
′
0+β
′
1X
′
1l
1 + eβ
′
0+β
′
1X
′
1l
)Zl(1− e
β′0+β
′
1X
′
1l
1 + eβ
′
0+β
′
1X
′
1l
)Nl−Zl
}{
e
−
τ
β′1
2
(β′1−µβ′1 )
2
}
,
g(β′0|D0, β′1) =
g(β′1, β
′
0|D0)
g(β′1|D0)
=
g(β′1, β
′
0|D0)∫
g(β′1, β
′
0|D0) dβ′0
=
{∏1
l=0(
eβ
′
0+β
′
1X
′
1l
1+e
β′0+β′1X′1l
)Zl(1− eβ
′
0+β
′
1X
′
1l
1+e
β′0+β′1X′1l
)Nl−Zl
}{
e
−
τ
β′0
2
(β′0−µβ′0 )
2
}
∫ {∏1
l=0(
e
β′0+β′1X′1l
1+e
β′0+β′1X′1l
)Zl(1− eβ
′
0+β
′
1X
′
1l
1+e
β′0+β′1X′1l
)Nl−Zl
}{
e
−
τ
β′0
2
(β′0−µβ′0 )
2
}
dβ′0
∝
{
1∏
l=0
{ e
β′0+β
′
1X
′
1l
1 + eβ
′
0+β
′
1X
′
1l
}Zl(1− e
β′0+β
′
1X
′
1l
1 + eβ
′
0+β
′
1X
′
1l
)Nl−Zl
}{
e
−
τ
β′0
2
(β′0−µβ′0 )
2
}
.
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Finally, we do power prior analysis (2.12) with both data D and D0 to
draw posterior samples of β1 from h(β1|D,D0, a). The augmented posterior of
β1,β0,b,τb,β
′
1,β
′
0,ρ1, µ1,τ1 is
h(β1, β0, b, τb, β
′
1, β
′
0, µ1, τ1, ρ1|D,D0, a)
=
h(β1, β0, b, τb, β
′
1, β
′
0, µ1, τ1, ρ1,D,D0, a)
h(D,D0, a)
∝ L(β1, β0|D, b)f(b|τb)f(τb)f(β0){L(β′1, β′0|D0)}ag(β′0)h(β1|µ1,Λ1)
h1(µ1|a1, R1)h1(τ1|κ1, ν1)h1(ρ1|c1, d1)
=
{
I∏
i=1
Ji∏
j=1
(
eβ0+β1X1i+bi
1 + eβ0+β1X1i+bi
)Yij(1− e
β0+β1X1i+bi
1 + eβ0+β1X1i+bi
)1−Yij
}{
I∏
i=1
√
τb
2pi
e−
1
2
b2i τb
}
{
νκbb
Γ(κb)
τκb−1b e
−νbτb
}{√
τβ0
2pi
e−
τβ0
2
(β0−µβ0 )2
}
{
1∏
l=0
(
eβ
′
0+β
′
1X
′
1l
1 + eβ
′
0+β
′
1X
′
1l
)Zl(1− e
β′0+β
′
1X
′
1l
1 + eβ
′
0+β
′
1X
′
1l
)Nl−Zl
}a
{√
τβ′0
2pi
e
−
τ
β′0
2
(β′0−µβ′0 )
2
}{
1
2pi
|Λ1| 12 e−
(β1−m1)′Λ1(β1−m1)
2
}{√
R1
2pi
e−
R1
2
(µ1−a1)2
}
{
νκ11
Γ(κ1)
τκ1−11 e
−ν1τ1
}{
ρc1−11 (1− ρ1)d1−1
B(c1, d1)
}
∝
{
I∏
i=1
Ji∏
j=1
(
eβ0+β1X1i+bi
1 + eβ0+β1X1i+bi
)Yij(1− e
β0+β1X1i+bi
1 + eβ0+β1X1i+bi
)1−Yij
}{
I∏
i=1
√
τbe
− 1
2
b2i τb
}
{
τκb−1b e
−νbτb}{e− τβ02 (β0−µβ0 )2}{ 1∏
l=0
(
eβ
′
0+β
′
1X
′
1l
1 + eβ
′
0+β
′
1X
′
1l
)Zl(1− e
β′0+β
′
1X
′
1l
1 + eβ
′
0+β
′
1X
′
1l
)Nl−Zl
}a
{
e
−
τ
β′0
2
(β′0−µβ′0 )
2
}{
|Λ1| 12 e−
(β1−m1)′Λ1(β1−m1)
2
}{
e−
R1
2
(µ1−a1)2
}
{
τκ1−11 e
−ν1τ1}{ρc1−11 (1− ρ1)d1−1} ,
so the full conditionals of β1,β0,b,τb,β
′
1, β
′
0,ρ1, µ1 and τ1 are
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h(β1|D,D0, a, β0, b, τb, β′1, β′0, µ1, τ1, ρ1)
= h(β1|D, β0, b, β′1, µ1, τ1, ρ1)
=
h(β1, β0, b, τb, β
′
1, β
′
0, µ1, τ1, ρ1|D,D0, a)∫
h(β1, β0, b, τb, β′1, β
′
0, µ1, τ1, ρ1|D,D0, a) dβ1
=
{∏I
i=1
∏Ji
j=1(
eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)Yij(1− eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)1−Yij
}{
|Λh| 12 e−
(β1−m1)′Λ1(β1−m1)
2
}
∫ {∏I
i=1
∏Ji
j=1(
eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)Yij(1− eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)1−Yij
}{
|Λh| 12 e−
(β1−m1)′Λ1(β1−m1)
2
}
dβ1
∝
{
I∏
i=1
Ji∏
j=1
(
eβ0+β1X1i+bi
1 + eβ0+β1X1i+bi
)Yij(1− e
β0+β1X1i+bi
1 + eβ0+β1X1i+bi
)1−Yij
}{
|Λh| 12 e−
(β1−m1)′Λ1(β1−m1)
2
}
∝
{
I∏
i=1
Ji∏
j=1
(
eβ0+β1X1i+bi
1 + eβ0+β1X1i+bi
)Yij(1− e
β0+β1X1i+bi
1 + eβ0+β1X1i+bi
)1−Yij
}
{
e
− τ1
2(1−ρ21)
{(β1−µ1)2−2ρ1(β1−µ1)(β′1−µ1)}
}
,
h(β0|D,D0, a, β1, b, τb, β′1, β′0, µ1, τ1, ρ1)
= h(β0|D, β1, b)
=
h(β1, β0, b, τb, β
′
1, β
′
0, µ1, τ1, ρ1|D,D0, a)∫
h(β1, β0, b, τb, β′1, β
′
0, µ1, τ1, ρ1|D,D0, a) dβ0
=
{∏I
i=1
∏Ji
j=1(
eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)Yij(1− eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)1−Yij
}{
e−
τβ0
2
(β0−µβ0 )2
}
∫ {∏I
i=1
∏Ji
j=1(
eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)Yij(1− eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)1−Yij
}{
e−
τβ0
2
(β0−µβ0 )2
}
dβ0
∝
{
I∏
i=1
Ji∏
j=1
(
eβ0+β1X1i+bi
1 + eβ0+β1X1i+bi
)Yij(1− e
β0+β1X1i+bi
1 + eβ0+β1X1i+bi
)1−Yij
}{
e−
τβ0
2
(β0−µβ0 )2
}
,
h(b|D,D0, a, β1, β0, τb, β′1, β′0, µ1, τ1, ρ1)
= h(b|D, β0, β1, τb)
=
h(β1, β0, b, τb, β
′
1, β
′
0, µ1, τ1, ρ1|D,D0, a)∫ ·· · ∫ h(β1, β0, b, τb, β′1, β′0, µ1, τ1, ρ1|D,D0, a) db
=
{∏I
i=1
∏Ji
j=1(
eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)Yij(1− eβ0+β1X1i+bi
1+eβ0+β1X1i+bi
)1−Yij
}{∏I
i=1
√
τbe
− 1
2
b2i τb
}
∫ ·· · ∫ {∏Ii=1∏Jij=1( eβ0+β1X1i+bi1+eβ0+β1X1i+bi )Yij(1− eβ0+β1X1i+bi1+eβ0+β1X1i+bi )1−Yij}{∏Ii=1√τbe− 12 b2i τb} db
∝
{
I∏
i=1
Ji∏
j=1
(
eβ0+β1X1i+bi
1 + eβ0+β1X1i+bi
)Yij(1− e
β0+β1X1i+bi
1 + eβ0+β1X1i+bi
)1−Yij
}{
I∏
i=1
√
τbe
− 1
2
b2i τb
}
,
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h(τb|D,D0, a, β1, β0, b, β′1, β′0, µ1, τ1, ρ1)
= h(τb|b)
=
h(β1, β0, b, τb, β
′
1, β
′
0, µ1, τ1, ρ1|D,D0, a)∫
h(β1, β0, b, τb, β′1, β
′
0, µ1, τ1, ρ1|D,D0, a) dτb
=
{∏I
i=1
√
τbe
− 1
2
b2i τb
}{
τκb−1b e
−νbτb}∫ {∏I
i=1
√
τbe
− 1
2
b2i τb
}{
τκb−1b e−νbτb
}
dτb
∝
{
I∏
i=1
√
τbe
− 1
2
b2i τb
}{
τκb−1b e
−νbτb}
∼ Gamma(κb + I
2
, νb +
∑I
i=1 b
2
i
2
),
h(β′1|D,D0, a, β1, β0, b, τb, β′0, µ1, τ1, ρ1)
= h(β′1|D0, a, β′0, β1, µ1, τ1, ρ1)
=
h(β1, β0, b, τb, β
′
1, β
′
0, µ1, τ1, ρ1|D,D0, a)∫
h(β1, β0, b, τb, β′1, β
′
0, µ1, τ1, ρ1|D,D0, a) dβ′1
=
{∏1
l=0(
eβ
′
0+β
′
1X
′
1l
1+e
β′0+β′1X′1l
)Zl(1− eβ
′
0+β
′
1X
′
1l
1+e
β′0+β′1X′1l
)Nl−Zl
}a {
|Λ1| 12 e−
(β1−m1)′Λ1(β1−m1)
2
}
∫ {∏1
l=0(
e
β′0+β′1X′1l
1+e
β′0+β′1X′1l
)Zl(1− eβ
′
0+β
′
1X
′
1l
1+e
β′0+β′1X′1l
)Nl−Zl
}a {
|Λ1| 12 e−
(β1−m1)′Λ1(β1−m1)
2
}
dβ′1
∝
{
1∏
l=0
(
eβ
′
0+β
′
1X
′
1l
1 + eβ
′
0+β
′
1X
′
1l
)Zl(1− e
β′0+β
′
1X
′
1l
1 + eβ
′
0+β
′
1X
′
1l
)Nl−Zl
}a{
|Λ1| 12 e−
(β1−m1)′Λ1(β1−m1)
2
}
∝
{
1∏
l=0
(
eβ
′
0+β
′
1X
′
1l
1 + eβ
′
0+β
′
1X
′
1l
)Zl(1− e
β′0+β
′
1X
′
1l
1 + eβ
′
0+β
′
1X
′
1l
)Nl−Zl
}a{
e
− τ1
2(1−ρ21)
{(β′1−µ1)2−2ρ1(β1−µ1)(β′1−µ1)}
}
,
h(β′0|D,D0, a, β1, β0, b, τb, β′1, µ1, τ1, ρ1)
= h(β′0|D0, a, β′1)
=
h(β1, β0, b, τb, β
′
1, β
′
0, µ1, τ1, ρ1|D,D0, a)∫
h(β1, β0, b, τb, β′1, β
′
0, µ1, τ1, ρ1|D,D0, a) dβ′0
=
{∏1
l=0(
eβ
′
0+β
′
1X
′
1l
1+e
β′0+β′1X′1l
)Zl(1− eβ
′
0+β
′
1X
′
1l
1+e
β′0+β′1X′1l
)Nl−Zl
}a
e
−
τ
β′0
2
(β′0−µβ′0 )
2
∫ {∏1
l=0(
e
β′0+β′1X′1l
1+e
β′0+β′1X′1l
)Zl(1− eβ
′
0+β
′
1X
′
1l
1+e
β′0+β′1X′1l
)Nl−Zl
}a
e
−
τ
β′0
2
(β′0−µβ′0 )
2
dβ′0
∝
{
1∏
l=0
(
eβ
′
0+β
′
1X
′
1l
1 + eβ
′
0+β
′
1X
′
1l
)Zl(1− e
β′0+β
′
1X
′
1l
1 + eβ
′
0+β
′
1X
′
1l
)Nl−Zl
}a
e
−
τ
β′0
2
(β′0−µβ′0 )
2
,
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h(ρ1|D,D0, a, β1, β0, b, τb, β′1, β′0, µ1, τ1)
= h(ρ1|β1, β′1, µ1, τ1)
=
h(β1, β0, b, τb, β
′
1, β
′
0, µ1, τ1, ρ1|D,D0, a)∫
h(β1, β0, b, τb, β′1, β
′
0, µ1, τ1, ρ1|D,D0, a) dρ1
=
{
|Λ1| 12 e−
(β1−m1)′Λ1(β1−m1)
2
}{
ρc1−11 (1− ρ1)d1−1
}
∫ {|Λ1| 12 e− (β1−m1)′Λ1(β1−m1)2 }{ρc1−11 (1− ρ1)d1−1} dρ1
∝
{
|Λ1| 12 e−
(β1−m1)′Λ1(β1−m1)
2
}{
ρc1−11 (1− ρ1)d1−1
}
∝ ρc1−11 (1− ρ1)d1−1e
−τ1 (β1−µ1)
2−2ρ1(β1−µ1)(β′1−µ1)+(β′1−µ1)2
2(1−ρ21) .
h(µ1|D,D0, a, β1, β0, b, τb, β′1, β′0, τ1, ρ1)
= h(µ1|β1, β′1, τ1, ρ1)
=
h(β1, β0, b, τb, β
′
1, β
′
0, µ1, τ1, ρ1|D,D0, a)∫
h(β1, β0, b, τb, β′1, β
′
0, µ1, τ1, ρ1|D,D0, a) dµ1
=
{
|Λ1| 12 e−
(β1−m1)′Λ1(β1−m1)
2
}{
e−
R1
2
(µ1−a1)2
}
∫ {|Λ1| 12 e− (β1−m1)′Λ1(β1−m1)2 }{e−R12 (µ1−a1)2} dµ1
∝
{
|Λ1| 12 e−
(β1−m1)′Λ1(β1−m1)
2
}{
e−
R1
2
(µ1−a1)2
}
∝ e− 12{(β1−m1)′Λ1(β1−m1)+R1(µ1−a1)2}
∝ e
− 1
2
(
2τ1
1+ρ1
+R1)(µ1−
τ1
1+ρ1
(β1+β
′
1)+R1a1
2τ1
1+ρ1
+R1
)2
∼ N(
τ1
1+ρ1
(β1 + β
′
1) +R1a1
2τ1
1+ρ1
+R1
,
2τ1
1 + ρ1
+R1),
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h(τ1|D,D0, a, β1, β0, b, τb, β′1, β′0, µ1, ρ1)
= h(τ1|β1, β′1, µ1, ρ1)
=
h(β1, β0, b, τb, β
′
1, β
′
0, µ1, τ1, ρ1|D,D0, a)∫
h(β1, β0, b, τb, β′1, β
′
0, µ1, τ1, ρ1|D,D0, a) dτ1
=
{
|Λ1| 12 e−
(β1−m1)′Λ1(β1−m1)
2
}{
τκ1−11 e
−ν1τ1}∫ {|Λ1| 12 e− (β1−m1)′Λ1(β1−m1)2 }{τκ1−11 e−ν1τ1} dτ1
∝
{
|Λ1| 12 e−
(β1−m1)′Λ1(β1−m1)
2
}{
τκ1−11 e
−ν1τ1}
= τ
κ1+
1
2
−1
1 e
−τ1(ν1+ (β1−µ1)
2−2ρ1(β1−µ1)(β′1−µ1)+(β′1−µ1)2
2(1−ρ21)
)
∼ Gamma(κ1 + 1
2
, ν1 +
(β1 − µ1)2 − 2ρ1(β1 − µ1)(β′1 − µ1) + (β′1 − µ1)2
2(1− ρ21)
),
The Metropolis Hastings Component of the Hybrid Algorithm
When Gibbs algorithm is used to draw posterior samples of β1 from f(β1|D), β′1
from g(β′1|D0) or β1 from h(β1|D,D0, a), some of the full conditionals do not have
closed forms. So we construct a markov chain with the full conditional as target
distribution to get the corresponding posterior samples. This is the MH part of the
hybrid algorithm. We develop a random walk MH algorithm with a t proposal density.
Since the algorithm can be implemented for the parameters in the same way, we write
the MH algorithm in a more general notation.
We write the parameter of interest and the nuisance parameters as θ and θ′,
respectively, and write the data by Dg. Assuming the full conditional is k(θ|Dg,θ′),
we note that the MH part of the hybrid algorithm for θ can be carried out as follows.
1. Start with θ0 and set m = 1.
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2. Sample θ∗ ∼ t(θm−1, νt), and accept θ∗ with probability
min{1, k(θ
∗|Dg,θ′)
k(θm−1|Dg,θ′)
},
and set θm = θ∗. Otherwise, set θm = θm−1.
3. Increase m by 1 and return to step 2.
Here t(θm−1, νt) is the univariate or multivariate t distribution with θ
m−1 and νt as
the location and degree of freedom, depending on whether θ is a random variable or
vector. With this hybrid algorithm, the posterior samples of θ are drawn from its
posterior k(θ|Dg).
2.5 Simulation Studies
2.5.1 Simulation Settings and Data Generation
A simulation study was carried out to examine the performance of the power prior
method in a two-arm cluster randomized trial with a binary outcome. Without loss of
generality, we assumed both current and historical trials were balanced in treatment
group size. The model for generating the current data D was Yij ∼ Bernoulli(pi),
logit(pi) = β0 +β1X1i + bi, i = 1, 2, . . . , I, j = 1, 2, . . . , J , bi ∼ N(0, τb), and the model
for generating historical data D0 was Zl ∼ Binomial(N, ql), logit(ql) = β′0+β′1X ′1l, l =
0, 1. In all simulated datasets, we assumed the first half of X1i were 0, and the
remaining were 1. X ′1l = 0 if l = 0 and 1 otherwise.
Five different scenarios were considered, which were designed to investigate
the effect of (1) the treatment effect (β1, β
′
1); (2) the historical sample size N ; (3) the
total cluster number I; (4) the cluster size J ; and (5) the intra cluster correlation
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coefficient (ICC) ρ in current trial, where ρ = 1
1+pi
2
3
τb
. We considered four unique
precision values τb = 0.199, 0.463, 1, 2.687, which corresponded to the ICC values
ρ = 0.604, 0.396, 0.233, 0.102. The settings of current and historical trials were given
in Tables 2.1− 2.2, respectively.
The two treatment effects were assumed to be exchangeable in the power
prior method, and this assumption implied that β1 and β
′
1 were random variables.
Conceptually, the joint distribution of β1 and β
′
1 should be specified to generate
multiple replicates of (β1,β
′
1) for use. However, this strategy was too computationally
extensive to be feasible in practice. Instead, we could just consider a few typical
values of (β1, β
′
1), and it could depict the profile of the effect of (β1, β
′
1).
In each scenario, 1, 000 simulated datasets were generated, and for each sim-
ulated dataset, the power prior method was applied with four different discounting
fractions, i.e. 0, 1, asym and aasym. The posterior median, standard deviation (SD) and
the 95% highest posterior density (HPD) interval of β1 were computed. Furthermore,
the 95% HPD interval was used to test the null hypothesis H0 : E(β1|D,D0) = 0.
With the 1, 000 simulated datasets, the average of the posterior medians, the average
of the posterior SDs, the relative bias, the root of the mean squared error (rMSE) as
well as the average length, the coverage probability (CP) and rejection probability
(RP) of the 95% HPD interval were calculated. The RP was just the type I error rate
when the true value of β1 was 0 or power otherwise.
Given a specific scenario, the simulation study was carried out as follows.
1. Generate current data D with (I, J, β0, β1, τb) from Table 2.1 and generate his-
torical data D0 with (N, β
′
0, β
′
1) from Table 2.2.
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2. Fit current data D with Model (2.4) and get the posterior samples of β1 from
f(β1|D) with the MH within Gibbs algorithm, and fit historical data D0 with
Model (2.5) and get the posterior samples of β′1 from g(β
′
1|D0) with the same
algorithm.
3. Calculate the symmetric and asymmetric KL divergences with k-NN algorithm
by using these two posterior samples, and take them as the symmetric and
asymmetric discounting fractions after the inverse exponential transformation.
4. Do the power prior analysis under four different discounting fractions, i.e. 0, 1,
asym and aasym. In each case, get a posterior sample of β1 from h(β1|D,D0, a)
with the MH within Gibbs algorithm.
5. Calculate the posterior median, SD and 95% HPD interval with the posterior
samples from h(β1|D,D0, a), and calculate the 95% HPD interval with the
posterior samples from h(β1|D,D0, a) and use it to determine (1) its length L,
(2) whether it covers the true value of β1, and let C = 1 if true and 0 otherwise,
(3) and whether it covers 0, and let R = 1 if true and 0 otherwise.
6. Repeat the above steps 1, 000 times, and report the average of the discounting
fractions asym and aasym and the average of the posterior median, the average of
the posterior SD, the relative bias and root of the mean squared error (rMSE).
In addition, report the average of L, C and R as the average length, CP and
RP of the 95% HPD interval.
In the MH within Gibbs algorithm, one Markov Chain of length 2, 500 was run
with the first 1, 500 samples discarded and the thinning rate being 5 in the separate
data analysis of current and historical trials under non-informative prior, while one
Markov Chain of length 5, 000 was run with the first 2, 500 samples discarded and the
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thinning rate being 5 in the power prior analysis. In both cases, the degree of freedom
in the t proposal density, νt, was set to be 3. The MCMC convergence was diagnosed
with the trace plot. When fitting the current data alone with model (2.4), we specified
non-informative uniform prior for τb instead of non-informative gamma prior because
the former is more robust in hierarchical models (Browne et al., 2006; Gelman et al.,
2006). In the k-NN algorithm, the maximum number of nearest neighbors to search,
k, was set to be 100.
2.5.2 Simulation Results
For illustrative purpose, here we only reported the discounting fraction estimate, the
posterior SD, the rMSE of the posterior median and the RP of the 95% HPD interval
for (1) β1 = log(1) = 0 in scenario 1; (2) β1 = log(4) ≈ 1.386 in scenario 1; (3)
N = 1, 000 in scenario 2; (4) I = 10 in scenario 3; (5) J = 10 in scenario 4; and (6)
τb = 0.463 in scenario 5, i.e. ρ = 0.396. All these results are summarized in Figures
2.1− 2.6. The other results could be obtained from the authors once requested.
Figures 2.1 and 2.2 showed that asym and aasym would increase as β′1 got closer
to β1, but they would never attach 1 even when β1 and β
′
1 were equal. This was
because asym and aasym measured the homogeneity of the two sources of data rather
than the similarity between the two treatment effects. Secondly, as asym and aasym
became larger, more percentage of historical information would be incorporated, and
as a result, the posterior SD and rMSE became smaller and the type I error rate and
power would increase. However, the maximum value of power did not achieve at the
maximum value of the discounting fraction. This was because the total amount of
historical information was not largest at that time.
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Compare Figures 2.3 − 2.6 to Figure 2.2, we could study the effects of N , I,
J and ρ on asym, aasym, SD, rMSE and power. asym and aasym would get smaller as
N and ρ increased and I decreased, but J seemed to have little effect on these two
discounting fractions. This was a good property because it meant the power prior
procedure did not allow the historical information to dominate current data analysis.
In addition, SD and rMSE became smaller and power became higher as I and J
increased and ρ decreased, but they were not affected greatly by N . Therefore, given
a current trial, the use of a more similar rather than larger historical trial played a
key role in improving the precision of the estimate and boosting the power.
Although Figures 2.2 − 2.6 demonstrated that the power prior method could
increase the power compared to not borrowing any historical information when his-
torical treatment lay in certain range of current one, Figure 2.1 showed that the type
I error rate was inflated at the same time. Therefore, it was hard to see how much
the auxiliary information contributed to the net gain in power. Though it was not
possible to control the type I error rate at the same value across different methods
for comparing the gain in power in simulation studies, Figures 2.1−2.6 still delivered
some useful information. For example, in Figure 2.2, when β′1 = log(5), asymmetric
discounting fraction resulted in a larger power than symmetric one, and Figure 2.1
showed that asymmetric discounting fraction led to a smaller type I error rate at the
same point. It meant that asymmetric discounting fraction had a better performance
in inference than symmetric one in that case. However, this might be just a local
property and could not be straightforwardly extended to its neighborhood because
the power function was not necessarily smooth.
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2.6 Example
2.6.1 Data Source
To illustrate, we applied the proposed method in the analysis of a two-arm cluster
randomized trial. The trial was sponsored by Merck Pharmaceutical and it was
designed to assess the efficacy of an electronic vaccination reminder intervention,
aimed at improving the first dosing uptake of a quadrivalent human papillomavirus
(HPV) vaccine in children and adolescents. The trial was conducted in five pediatric
clinics, started in Feb. 2015. All pediatricians and nurse practitioners who provided
health care at the participating clinics were included in the trial. Randomization was
performed at the physician level. Specifically, 30 physicians were randomly assigned
to one of the two arms. Nineteen physicians were assigned to the intervention arm,
and 11 in the control arm. In the intervention arm, immunization reminders were
delivered to the physician through an electronic medical record system. The system
determined patient’s eligibility of receiving the HPV vaccine. Physicians of eligible
patients received reminders when patient was present in the clinic. No reminders
were provided for patients of physicians in the control group, although the control
physicians retained the rights to order vaccination as they saw fit. Patients eligible for
HPV vaccination under the care of intervention or control physicians were recruited
for study participation. Within one year of the study period, a total of 475 eligible
patients were recruited. Numbers of patients seen by each physician (i.e., the cluster
size) varied by physician, ranged from 1 to 55.
There is a sizable literature on vaccine reminder interventions, with different
scripts and contents, for different clinical populations. Modes of message delivery
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also varied. For illustration, we selected a simple randomized trial conducted by
Szilagyi et al. (2011) between Oct. 2007 and Dec. 2008 as the historical trial. As in
the current trial, this historical trial was also a two-arm trial on the efficacy of one
reminder intervention on the uptake rate of the first dose of the HPV vaccine. The
intervention messages were also delivered to the patients. The trial did not include
male children. Briefly, 1055 and 1084 eligible girls were recruited and randomized to
the control and intervention arm, respectively, and at the end of the study, 453 and
634 girls received the first dose of HPV vaccine in two treatment arms.
2.6.2 Analytical Results
We analyzed the historical data with Model (2.5) and performed power prior analysis
(2.12) to the current data by using the historical data under four discounting fractions,
i.e. 0,1,asym and aasym. The power prior analysis under the discounting fraction 0 was
equivalent to analyze the current data with Model (2.4). All analytic results were
summarized in Table 2.3, and they were labeled Analysis 1− 5 accordingly.
The results in Table 2.3 demonstrated that incorporation of historical infor-
mation into current data analysis could reduce the standard deviation and the length
of the 95% HPD interval compared to not borrowing any historical evidence, and
the more historical information the power prior procedure borrowed, the larger the
reduction was. However, the precision of the treatment effect estimate yielded by the
power prior procedure was higher than that by historical data analysis alone. It meant
that the amount of current information plus the discounted historical information was
less than the total historical information. Furthermore, the treatment effect estimate
from the power prior procedure lay between those from separate data analysis of both
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trials, and it implied that the power prior procedure would shrink the current treat-
ment effect towards the historical one. Separate data analysis results showed that the
95% HPD interval of the current treatment effect covered 0 and that of the historical
treatment effect did not, which induced the conclusion that the current treatment
effect was not significant but the historical treatment effect was. When borrowing
historical information through power prior under the symmetric discounting fraction,
the same conclusion about the current treatment effect was made though the 95%
HPD interval became narrower. When asymmetric discounting fraction was adopted,
more historical strength was borrowed, then the opposite conclusion was made, that
is, the current treatment effect was significant.
2.7 Discussion
In this chapter, a Bayesian power prior method was developed to analyze the treat-
ment effect in a two-arm cluster randomized trial of binary outcome. A novel power
prior was constructed under the assumption that the treatment effects in the two
trials were exchangeable, and a new discounting fraction function was proposed as
the inverse exponential transformation of the Kullback Leibler divergence of the pos-
terior distributions of the two treatment effects, which were derived from Bayesian
data analysis of the two trials under non-informative priors separately. Through the
power prior, the historical information of the treatment effect could be appropriately
incorporated into the current data analysis, thereby decreasing the variability of the
treatment effect estimate as well as boosting the power with non-significant inflation
of type I error rate in certain situations compared to not borrowing external evidence.
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The inverse exponential transformation was adopted in the construction of the
discounting fraction function, and therefore the power prior was identified with this
discounting fraction function. Such a power prior could help increase the power, but
it would also slightly inflate the type I error rate. This meant the inverse exponential
transformation might not be the optimal one. Future work can be done to find out
another transformation function that results in a better trade off between type I
error rate inflation and power increase. Another limit is that this power prior is not
compared to other types of power priors (Ibrahim et al., 2015). Such a comparison
would help demonstrate the merits and drawbacks of this power prior.
Additionally, only one historical trial was considered in this chapter, which
limited the use of this procedure in application because more than one historical
trials usually existed. Though a straightforward way to extend this method to the case
of multiple historical trials was mentioned in Equation (2.2), it brings cumbersome
and extensive computations when the number of historical trials available is large,
which makes such a simple extension less attractive. One possible way to bypass this
dilemma is to pool the historical data first and then construct the power prior for the
meta data. But before taking this strategy, we need to prove its equivalence to the
first simple extension way. In the end, the power prior method provides a potential
to design a new two-arm cluster randomized trial of binary outcome by using relevant
historical data. One promising advantage of such a design strategy is that fewer
samples may be needed to achieve certain power compared to not borrowing any
external information. But since no explicit formula for sample size exists, a numerical
algorithm must be developed to address the sample size determination problem.
31
Table 2.1: Setting of two-arm current trial with binary outcome
Scenario I J β0 β1 τb
1 20 20 −0.1 log(1), log(2), . . . , log(6) 1
2 20 20 −0.1 log(4) 1
3 10, 20, 40 20 −0.1 log(4) 1
4 20 10, 20, 40 −0.1 log(4) 1
5 20 20 −0.1 log(4) 0.199, 0.463, 1, 2.687
Table 2.2: Setting of two-arm historical trial with binary outcome
Scenario N β′0 β
′
1
1 200 0.1 log(1), log(2), . . . , log(6)
2 100, 200, 400, 800, 1000 0.1 log(1), log(2), . . . , log(6)
3 200 0.1 log(1), log(2), . . . , log(6)
4 200 0.1 log(1), log(2), . . . , log(6)
5 200 0.1 log(1), log(2), . . . , log(6)
Table 2.3: Estimates of discounting fraction and intervention effect
Analysis Discounting fraction Posterior median Posterior SD 95% HPD interval
1 0.628 0.087 [0.458, 0.798]
2 0 0.808 0.452 [−0.122, 1.659]
3 1 0.749 0.379 [0.047, 1.601]
4 0.075 0.759 0.424 [−0.091, 1.612]
5 0.262 0.747 0.405 [0.013, 1.638]
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Figure 2.1: In two-arm trials with binary outcome, the effect of the historical treatment
effect β′1 on the discounting fraction, SD, rMSE and type I error rate where the treatment
effect β1 = log(1) = 0, the total number of cluster I = 20, the cluster size J = 20 and the
ICC ρ = 0.233 in current trial and the arm size N = 200 in historical trial
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Figure 2.2: In two-arm trials with binary outcome, the effect of the historical treatment
effect β′1 on the discounting fraction, SD, rMSE and power where the treatment effect
β1 = log(4) ≈ 1.386, the total number of cluster I = 20, the cluster size J = 20 and the
ICC ρ = 0.233 in current trial and the arm size N = 200 in historical trial
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Figure 2.3: In two-arm trials with binary outcome, the effect of the historical treatment
effect β′1 on the discounting fraction, SD, rMSE and power where the treatment effect
β1 = log(4) ≈ 1.386, the total number of cluster I = 20, the cluster size J = 20 and the
ICC ρ = 0.233 in current trial and the arm size N = 1000 in historical trial
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Figure 2.4: In two-arm trials with binary outcome, the effect of the historical treatment
effect β′1 on the discounting fraction, SD, rMSE and power where the treatment effect
β1 = log(4) ≈ 1.386, the total number of cluster I = 10, the cluster size J = 20 and the
ICC ρ = 0.233 in current trial and the arm size N = 200 in historical trial
36
0.0 0.5 1.0 1.5
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
β1’
D
is
co
un
tin
g 
Fr
a
ct
io
n
asym_fraction
sym_fraction
zero_fraction
one_fraction
0.0 0.5 1.0 1.5
0.
54
0.
56
0.
58
0.
60
0.
62
β1’
SD
0.0 0.5 1.0 1.5
0.
54
0.
56
0.
58
0.
60
0.
62
β1’
rM
SE
0.0 0.5 1.0 1.5
0.
55
0.
65
0.
75
β1’
Po
w
e
r
Figure 2.5: In two-arm trials with binary outcome, the effect of the historical treatment
effect β′1 on the discounting fraction, SD, rMSE and power where the treatment effect
β1 = log(4) ≈ 1.386, the total number of cluster I = 20, the cluster size J = 10 and the
ICC ρ = 0.233 in current trial and the arm size N = 200 in historical trial
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Figure 2.6: In two-arm trials with binary outcome, the effect of the historical treatment
effect β′1 on the discounting fraction, SD, rMSE and power where the treatment effect
β1 = log(4) ≈ 1.386, the total number of cluster I = 10, the cluster size J = 20 and the
ICC ρ = 0.396 in current trial and the arm size N = 200 in historical trial
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Chapter 3
Design of Two-arm Cluster Randomized Trials with Binary Outcome
3.1 Cluster Randomized Trial Design
Sample size determination is an important task in the design of clinical trials. For
cluster randomized trials, sample size calculation is complicated because the random-
ization at the cluster level creates an interdependency among the subjects within the
same cluster. As a result, and the power of the analysis depends not only on the
numbers of clusters and patients, but also the strength of intra-cluster correlation
(ICC) (Donner, 1992; Donner and Klar, 1994; Kerry and Bland, 1998). A sample size
formula for binary outcomes is presented by Donner and Klar (2000).
For all practical purposes, the true values of ICC are often unknown, so they
have to be estimated based either on expert opinions or on pilot data. In some
situations, the maximum value of ICC is used to ensure a conservative power estimate
(Rotondi and Donner, 2009). Sensitivity analysis is often performed to evaluate the
influences of different ICC values (Turner et al., 2005).
Further complicating the power analysis is the unequal cluster size. In the
case of varying cluster sizes, analysts often use the average size of the clusters in the
standard sample size formulae. While the method is simple to use, its accuracy is
often less than certain. In some situations, the cluster size is assumed to be a random
variable, and new formulae are developed to accommodate the power calculation
(Kong et al., 2003; Manatunga et al., 2001).
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An alternative approach for calculating the power and sample size is to con-
duct a simulation study. Simulation-based power analysis tends to be more flexible in
its accommodation of the trial parameters, including ICC values, number of clusters,
cluster sizes, and desired significance levels, etc (Turner et al., 2005, 2004). In the cur-
rent research context, it is possible to take into account of the influences of historical
data, in ways described in the previous chapter. Similar approaches have been used
by others, eg. Wang and Gelfand (2002) in a fully Bayesian context. They proposed
to elicit an informative prior on the treatment effect from the historical information,
which was referred to as the sampling prior, and then developed a simulation-based
algorithm to determine the sample size under the pre-specified sampling prior. To
implement, the treatment effects are generated from the sampling prior, then data
replicates are generated from the model under a given sample size. Then they fitted
the same model under different data replicates, the new priors were referred to as the
fitting prior. Analytical power was estimated from the number of times of rejecting
the null hypothesis under the simulated data.
Notably, this fully Bayesian approach does not preserve the interpretation of
the traditional trial concepts, such as type I and type II error rates because the
treatment itself is viewed as random. Along the same vein, other Bayesian inference
approaches have been developed under the decision theoretical framework (Pezeshk,
2003), which built upon the concepts of the average coverage criterion (ACC), average
length criterion (ALC), Bayes factor, loss and utility functions, and etc (Berger, 2013;
Weiss, 1997).
To retain the basic frequentist trial concepts, Stamey et al. (2013) proposed to
use a point mass prior for the treatment effect as the sampling prior. In its essence,
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this modified method is not fully Bayesian. Instead, it only used Bayesian techniques
to design a new trial under the traditional criteria.
In this dissertation, we propose a simulation scheme by which we could esti-
mate the analytical power, while incorporating the previous trial data through a power
prior, along the lines of Hobbs and Carlin (2007) and Ibrahim and Chen (2000).
3.2 Designing Trials Using Bayesian Power Priors
Power prior has been used previously in designing various types of clinical trials,
including non-inferiority trials, one-sided superiority trials, and even sequential trials
(Chen et al., 2014, 2011, 2014; Ibrahim et al., 2012). To the best of our knowledge, the
method has not been used to design superiority cluster randomized trials. Assuming
that one historical datasetD0 is available, following Model (2.5), we aim at developing
a simulation scheme through which we could estimate the analytical power for a two-
arm cluster randomized trial with a binary outcome.
In this context, the sample size consists of cluster number and cluster size. For
the purpose of illustration, we determine the number of clusters with fixed cluster size.
We assume the current data D come from Model (2.4), which involves three param-
eters, β0, β1 and τb, where β1 is the treatment effect and the other two parameters
can be considered as nuisance ones. Then the two-sided superiority test is
H0 : E(β1|D,D0) = 0 v.s. H1 : E(β1|D,D0) 6= 0. (3.1)
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We determine the minimal cluster number that controls the type I error rate
for less than or equal to α1, and power greater than or equal to α2. Here α1 and α2
are user-specified threshold values, and typical values are 0.05 and 0.8, respectively.
We assume the sampling prior pis(β0, β1, τb) = pi
s(β0)pi
s(β1)pi
s(τb), where pi
s(β1)
is a point mass prior pis0(β1) = 1 under the null hypothesis for calculation of type I
error rate, and any prior pis1(β1) with its support as a subset of {β1 : β1 6= 0} in the
calculation of power. A simple example is the point mass prior pis1(β1) = 1 when
β1 = β
?
1 , where β
?
1 is any nonzero value. No constraints are imposed on pi
s(β0) and
pis(τb), and they are typically specified as point mass priors. In addition, we assume
the fitting prior is pif (β0, β1, τb) = pi
f (β0)pi
f (β1)pi
f (τb), where pi
f (β1) is the power prior
(2.11), and no constraints are imposed on pif (β0) and pi
f (τb), and they are usually
specified as non-informative priors.
With the sampling prior pis(β0, β1, τb), the current data D can be generated
from Model (2.4), then the power prior analysis can be conducted to the data D
with the fitting prior pif (β0, β1, τb), and therefore the posterior of β1 (2.12) is yielded.
From this posterior, the (1− α)× 100% HPD interval of β1 can be determined, and
it is used to complete the inference (3.1). We reject H0 if the HPD interval does not
cover 0, and retain it otherwise.
This rejection probability is taken as the design quantity, which can be written
as
β1
I
s = Es{IND(P (β1 > 0|D, pif ) > 1−
α
2
) + IND(P (β1 < 0|D, pif ) > 1− α
2
)}, (3.2)
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where I is the experimental cluster number, IND is the indicator function, P (β1 >
0|D, pif ) > 1 − α
2
and P (β1 < 0|D, pif ) > 1 − α2 are respectively the event that the
α
2
th quantile of β1 is greater than 0 and the event that the (1 − α2 )th quantile of β1
is smaller than 0. These two events are determined with the posterior (2.12). The
expectation Es{·} is taken with respect to the marginal distribution of D under the
sampling prior pis(β0, β1, τb). This design quantity is exactly the type I error rate
when pis0(β1) is used, or the power when pi
s
1(β1) is used.
For given 0 < α1 < 1 and 0 < α2 < 1, we compute Iα1 = min{I : β1I0 ≤ α1}
and Iα2 = min{I : β1I1 ≥ α2}, where β1I0 and β1I1 are the design quantity (3.2) cal-
culated under the sampling prior pis0(β1) and pi
s
1(β1). Therefore, the Bayesian sample
size is
IB = max{Iα1 , Iα2}. (3.3)
However, the design quantity (3.2) does not have a closed form, so no closed
form formula for sample size exists in this context. To solve, we develop a simulation
based algorithm to search for the Bayesian sample size IB, as described below.
1. Specify α, α1, α2, M and K.
2. Set a value for I, the cluster number.
3. Generate data D from model (2.4), with the sampling prior pis(β0)pi
s(β1)pi
s(τb).
Use pis0(β1) to calculate type I error rate β1
I
0 and use pi
s
1(β1) to calculate power
β1
I
1.
4. Determine the symmetric and asymmetric discounting fractions (2.8) and (2.9),
with D and D0.
5. Construct the power prior of β1 (2.11) under the historical data D0, for each
discounting fraction.
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6. Conduct the power prior analysis (2.12) to the current data D with power prior
(2.11).
7. Let {β(1)1 , . . . , β(M)1 } be the posterior samples of β1 from (2.12). From the pos-
terior samples, calculate
Pˆ1 =
1
M
M∑
m=1
IND(β
(m)
1 > 0),
and
Pˆ2 =
1
M
M∑
m=1
IND(β
(m)
1 < 0),
where IND(·) is the indicator function.
8. Check whether Pˆ1 > 1 − α2 or Pˆ2 > 1 − α2 , and let R = 1 if it holds and 0
otherwise.
9. Repeat the steps 3− 8 K times, and compute the average of R in these K runs
as the rejection proportion, which is an estimate of the design quantity β1
I
s in
(3.2).
10. If the criteria β1
I
0 ≤ α1 and β1I1 ≥ α2 are not satisfied, or I is not the minimum
cluster number that makes the criteria hold, try another cluster number and
rerun the steps 2− 9 until the Bayesian sample size IB is found.
This Bayesian design is easily extendable to the determination of cluster size with
fixed cluster number as well as the case where multiple historical data are available.
3.3 Simulation Studies
A simulation study was designed to illustrate the process of power calculation. We
considered a situation where one historical data was available, and we assumed both
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current and historical trials were balanced in treatment group size. We considered
the determination of (1) the number of clusters with fixed cluster size; and (2) the
cluster size with a fixed number of clusters. In both scenarios, the historical trial had
N = 1000,β′0 = 0.1,β
′
1 = log(4). The current trial configurations were given in Tables
3.1 and 3.2.
To design a clinical trial (i.e., the current trial), we assumed that the historical
data were given. In the simulation study, we first generated the historical data D0
from model (2.5) under a specific parameter setting. Separately we simulated the
current trial data. Then we determine the power under specific sample size using
the power prior analysis. We did not calculate the Bayesian sample size IB under
each current trial setting due to computation limit. Instead, we implemented the
algorithm (without the last step) with some cluster numbers I under each current
trial setting in the first scenario and some cluster sizes J under each current trial
setting in the second scenario. As a result, the rejection proportions for the null
hypothesis H0 : E(β1|D,D0) = 0 could be calculated. We tried cluster number
I = 10, 20, 30, 40 for each current trial setting in the first scenario, and cluster size
J = 10, 20, 30, 40 for each current trial setting in the second scenario. Therefore, for
each specific current trial setting, we could plot the profile of rejection proportion
against cluster number or cluster size, which could be used to propose a new I or J
to try further with the simulation based algorithm until IB is found.
In Tables 3.1 and 3.2, when the current trial setting in the first case was used,
the rejection proportion was an estimate of type I error rate, and power otherwise.
In the simulation based algorithm, we applied four different discounting fractions, i.e.
0, 1, asym and aasym. The first two discounting fractions were used for reference. pif (β0)
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and pif (τb) were non-informative priors, α = 0.05, α1 = 0.05, α2 = 0.8, M = 2, 500
and K = 1, 000. For the purpose of illustration, the profile of the rejection proportion
against cluster number I in the first scenario and that against cluster size J in the
second scenario were plotted in Figures 3.1 − 3.2. From the two Figures, we could
see the type I error rate was controlled after the historical information was borrowed
with our power prior method, and at the same time, fewer samples were needed to
achieve a pre-specified power.
3.4 Example
We assumed that historical trial data in the Example section of last chapter followed
model (2.5), and we used it to design a two-arm (balanced) cluster randomized trial
with a binary outcome. We conducted the trial design as what we did in the Simula-
tion Studies section above, and the only difference was that we replaced the simulated
historical data D0 with this real one. For illustrative purpose, the profile of the rejec-
tion proportion against cluster number I in the first scenario and that against cluster
size J in the second scenario were plotted in Figures 3.3−3.4. From these two figures,
we could read the same message as those from the simulation results.
3.5 Discussion
In this chapter, we used our novel power prior in designing a two-arm cluster random-
ized trial with binary outcome, and both simulation results and real data analytical
results were promising. They both demonstrated that fewer samples were needed to
achieve a pre-specified power after the historical information was borrowed with our
power prior method, and at the same time, the type I error rate was controlled.
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This method, however, had no explicit formula for sample size, and therefore
we developed a simulation-based algorithm to determine the sample size. This algo-
rithm was easy to understand in concept, and it was straightforward to operate as
well. But it was quite time consuming as it was based on simulations and therefore
extensive computations were needed. This drawback would prevent this method from
being used in applications. From the details of this algorithm described in this chap-
ter, we could see it consisted of several similar computations, and then the results
from them were pooled to yield the final results. So we used the parallel comput-
ing approach to solve this problem. In the parallel computing program, the similar
computation tasks could be done simultaneously on different cores of a computer,
and therefore the computation time was decreased compared to serial computing ap-
proach. The decrease in computing time was inversely proportional to the number of
cores available on the computer.
This power prior method has demonstrated its use in the design and analysis
of two-arm cluster randomized trial with binary outcome. Its value, however, would
be too limited if we could not extend it to more general situations, such as multi-
arm cluster randomized trials with outcome following arbitrary exponential family
distributions. This aim would be covered in the next chapter.
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Table 3.1: Current trial setting for the determination of cluster number in two-arm
trials with binary outcome
Case J β0 β1 τb
1 20 Unif(−0.1, 0.1) log(1) Unif(0.463, 1)
2 20 Unif(−0.1, 0.1) log(2) Unif(0.463, 1)
3 20 Unif(−0.1, 0.1) log(4) Unif(0.463, 1)
4 20 Unif(−0.1, 0.1) Unif(log(2), log(4)) Unif(0.463, 1)
Table 3.2: Current trial setting for the determination of cluster size in two-arm trials
with binary outcome
Case I β0 β1 τb
1 20 Unif(−0.1, 0.1) log(1) Unif(0.463, 1)
2 20 Unif(−0.1, 0.1) log(2) Unif(0.463, 1)
3 20 Unif(−0.1, 0.1) log(4) Unif(0.463, 1)
4 20 Unif(−0.1, 0.1) Unif(log(2), log(4)) Unif(0.463, 1)
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Figure 3.1: In two-arm trials with binary outcome, the profile of type I error rate and
power against cluster number I where the cluster size J = 20, β0 ∼ Unif(−0.1, 0.1), τb ∼
Unif(0.463, 1) in current trial and the arm size N = 1, 000, β′0 = 0.1, β′1 = log(4) in historical
trial
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Figure 3.2: In two-arm trials with binary outcome, the profile of type I error rate and
power against cluster size J where the cluster number I = 20, β0 ∼ Unif(−0.1, 0.1), τb ∼
Unif(0.463, 1) in current trial and the arm size N = 1, 000, β′0 = 0.1, β′1 = log(4) in historical
trial
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Figure 3.3: In two-arm trials with binary outcome, the profile of type I error rate and
power against cluster number I where the cluster size J = 20, β0 ∼ Unif(−0.1, 0.1), τb ∼
Unif(0.463, 1) in current trial and a real historical trial is used
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Figure 3.4: In two-arm trials with binary outcome, the profile of type I error rate and
power against cluster size J where the cluster number I = 20, β0 ∼ Unif(−0.1, 0.1), τb ∼
Unif(0.463, 1) in current trial and a real historical trial is used
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Chapter 4
Further Extensions
In this chapter, we extend the proposed method to situations of multi-arm cluster
randomized trials and outcomes following the exponential family distributions, and
thus including continuous, count, binary, and other categorical outcomes. We also
extend the method to accommodate both balanced and imbalanced designs. Modeling
details and computational techniques are largely parallel to those presented in the
previous chapters.
4.1 Cluster Randomized Trials: Notation
Suppose that the current trial consists of one control arm and P − 1 different treat-
ment arms, and the numbers of clusters in the control arm and the treatment arms are
I0 and Ip, p = 1, 2, . . . , P−1. So the total number of clusters is I = I0+I1+. . .+IP−1.
Let Ji be the number of subjects in the ith cluster, and Yij the outcome from the
jth subjects in the ith cluster following an exponential family distribution. We ad-
ditionally use P − 1 indicator variables X1i, X2i, . . . , XP−1i to indicate the treatment
assignment for the ith cluster. Specifically, if the ith cluster is in the pth treatment
arm, then all indicator variables take value 0 except for Xpi = 1. Under such nota-
tion, the current trial data can be written as D = {(Yij, X1i, X2i, . . . , XP−1i) : i =
1, 2, . . . , I, j = 1, 2, . . . , Ji}.
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For the historical trial, we assume that it has one control group and P − 1
similar treatment groups. Let l be the treatment group indicator, with 0 for the
control group and 1, 2, . . . , P − 1 for the corresponding treatment groups. Suppose
that the historical data come in a summary fashion. We let Nl be the number of
subjects in the lth arm, Zl be the summary statistic of individual outcomes in the
lth treatment group. In particular, Zl is a sufficient statistic of the mean of the
lth group. As in the current trial, we use indicator variables X ′1l, X
′
2l, . . . , X
′
P−1l to
indicates the treatment assignment. For the lth group, we all indicator variables
take value 0 except for X ′pl = 1. So the historical data can be written as D0 =
{(Zl, Nl, X ′1l, X ′2l, . . . , X ′P−1l) : l = 0, 1, . . . , P − 1}.
Suppose that the trial outcomes follow an exponential family distribution
f(Yij|bi) = exp{Yijηi − d(ηi)
a(φ)
+ c(Yij, φ)}, (4.1)
where ηi is the natural parameter, and φ a nuisance parameter. Let µi be the condi-
tional mean of Yij given bi, and it is related to ηi through a monotone invertible link
function k(·).
The outcomes are linked to the independent variables through the following
model
ηi = k(µi) = β0 +X
T
i β + bi, (4.2)
whereXTi = (X1i, X2i, . . . , XP−1i), β = (β1, β2, . . . , βP−1)
T is the (P−1)×1 coefficient
vector, and bi is the random effect associated with the ith cluster. For narrative
simplicity, we write b = (b1, b2, . . . , bI). As in the standard mixed effect generalized
linear models, we assume bi ∼ N(0, τb), β0 ∼ N(µβ0 , τβ0), βp ∼ N(µβp , τβp) and τb ∼
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Gamma(κb, νb). The nuisance parameter φ is not the parameter of primary interest
and its functional form varies among different members of the exponential family. For
example, φ is the precision parameter in normal distribution, and shape parameter in
Beta distribution. Without loss of generality, we assume that the prior for φ is f(φ|ζ),
where ζ is the hyper-parameter vector. Here βp represents the treatment effect of the
pth treatment arm under D.
Similarly, for the historical data D0, we assume that the individual outcomes
follow the same distribution as does the current trial outcome. We write the individual
outcomes in the lth group as Zil, i = 1, 2, . . . , Nl and l = 0, 1, . . . , P − 1
g(Zil) = exp{Zilη
′
l − d(η′l)
a(φ′)
+ c(Zil, φ
′)}, (4.3)
where η′l is the natural parameter, and φ
′ is the nuisance parameter. Therefore, the
joint distribution of (Z1l, Z2l, . . . , ZNll) is
g(Z1l, Z2l, . . . , ZNll) = exp{
η′l
∑Nl
i=1 Zil −Nld(η′l)
a(φ′)
+
Nl∑
i=1
c(Zil, φ
′)}
= exp{Zlη
′
l −Nld(η′l)
a(φ′)
}exp{
Nl∑
i=1
c(Zil, φ
′)}.
(4.4)
The sample sum Zl is a sufficient statistic for the natural parameter η
′
l by the
factorization theorem. We then derive the probability density function of Zl. From
Equation (4.4), we have
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g(Zl) =
∫
· · ·
∫
exp{Zlη
′
l −Nld(η′l)
a(φ′)
}exp{
Nl−1∑
i=1
c(Zil, φ
′)+c(Zl−
Nl−1∑
i=1
Zil, φ
′)} dZ1l . . . dZNl−1l,
(4.5)
under the transformation Z1l = Z1l, . . . , ZNl−1l = ZNl−1l, ZNll = Zl−
∑Nl−1
i=1 Zil as the
Jacobian determinant is 1.
For normal, count and binary outcomes, the distributions of the sufficient
statistic Zl are N(Nlη
′
l, Nla(φ
′)), Poisson(Nlexp(η′l)) and Binomial(Nl, logit
−1(η′l)), re-
spectively. Let µ′l be the mean of Zil, or equivalently the mean of
Zl
Nl
, and it is related
to η′l through the monotone invertible link function k(·).
Consider the following model
η′l = k(µ
′
l) = β
′
0 +X
′T
l β
′, (4.6)
where X ′Tl = (X
′
1l, X
′
2l, . . . , X
′
P−1l), β
′ = (β′1, β
′
2, . . . , β
′
P−1)
T is the (P − 1)× 1 coeffi-
cient vector. We further assume β′0 ∼ N(µβ′0 , τβ′0), β′p ∼ N(µβ′p , τβ′p), and the prior for
the nuisance parameter φ′ is g(φ′|ζ ′), where ζ ′ is the hyper-parameter vector, and β′p
stands for the treatment effect of the pth treatment group under D0.
4.2 Determination of Discounting Fractions
All priors for parameters in models (4.2) and (4.6) are assumed to be non-informative.
In separate data analysis, the posteriors of β and β′, denoted by f(β|D) and g(β′|D0),
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are evaluated, in the presence of closed forms. To implement, we use the MH algo-
rithm within Gibbs sampling to ascertain the corresponding posterior samples.
Since the two posteriors are derived under non-informative priors, they are not
influenced by external data other than the current and historical information. From
this, the symmetric and asymmetric KL divergence measures are defined to quantify
the similarity of the two data sources
DsymKL (f ||g) = Ef{log(
f
g
)}+ Eg{log( g
f
)}, (4.7)
DasymKL (f ||g) = Ef{log(
f
g
)}, (4.8)
where f and g stand for f(β|D) and g(β′|D0), and Ef{·} and Eg{·} are the expec-
tations taken with respect to f and g, respectively.
Then we propose the following discounting fractions
asym = e−D
sym
KL (f ||g) = e−D
sym
KL (g||f). (4.9)
aasym = e−D
asym
KL (f ||g), (4.10)
The two KL divergence measures are not easy to compute by definition, we
therefore use the k-Nearest Neighbor (k-NN) algorithm for calculation.
4.3 Estimation of Treatment Effect
We assume the pth treatment in the current trial is only the same or similar to that
in the historical trial, and therefore, for the estimation of βp, it is reasonable to allow
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the historical information be borrowed only through β′p. Under this assumption, we
assume βp and β
′
p are exchangeable. Denote βp = (βp, β
′
p), and we assume it follows a
bivariate normal distribution hp(βp|mp,Λp), with a mean vector mp = µp(1, 1)′ and
a 2 × 2 precision matrix Λp. Here, the precision and correlation parameters are τp
and ρp, respectively.
To complete the model specification, we assume the following hyper-prior dis-
tributions for µp, τp and ρp
hp(µp|ap, Rp) =
√
Rp
2pi
e−
Rp
2
(µp−ap)2 ,
hp(τp|κp, νp) = ν
κp
p
Γ(κp)
τκp−1p e
−νpτp ,
hp(ρp|cp, dp) = ρ
cp−1
p (1− ρp)dp−1
B(cp, dp)
,
where Γ(·) and B(·, ·) are respectively Gamma and Beta functions.
The power prior of β can therefore be written as
h(β|D0, a) ∝
∫
· · ·
∫
{
∫
(L(β′0,β
′|D0)ag(β′0) dβ′0}
P−1∏
p=1
{hp(βp|mp,Λp)
hp(µp|ap, Rp)hp(τp|κp, νp)hp(ρp|cp, dp)} dβ′ dµ dτ dρ,
(4.11)
where µ = (µ1, µ2, . . . , µP−1), τ = (τ1, τ2, . . . , τP−1) and ρ = (ρ1, ρ2, . . . , ρP−1),
L(β′0,β
′|D0) and g(β′0) are the likelihood and prior density function of β′0 and β′
in Model (4.6). From the power prior (4.11), we derive the posterior function of β as
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follows
h(β|D,D0, a) ∝
∫
· · ·
∫
{L(β0,β|D, b)f(b|τb)f(β0)f(τb) db dβ0 dτb}h(β|D0, a),
(4.12)
where L(β0,β|D, b), f(b|τb), f(β0) and f(τb) are the likelihood and prior density
functions in Model (4.2).
With the posterior (4.12), we can answer various questions about the treatment
effects. For examples,
1. Does the pth treatment has a nonzero effect? The hypothesis is equivalent to
testing H0 : E(βp|D,D0) = 0, for a given p = 1, 2, . . . , P − 1.
2. Is the effect of the pth treatment significantly different from that of the kth
treatment? The hypothesis is equivalent to testing H0 : E(γpk|D,D0) = 0,
where γpk = βp − βk, for k = 1, 2, . . . , P − 1, where k 6= p.
3. Do the P − 1 treatments have a similar effect? The hypothesis is equivalent to
testing H0 : E(β1|D,D0) = E(β2|D,D0) = · · · = E(βP−1|D,D0).
In case of all pairwise comparisons, one could adjust for inflated type I error
rates associated with multiple test, following an established method (Hsu, 1996).
For the first hypothesis, we rely on the posterior of βp
h(βp|D,D0, a) =
∫
· · ·
∫
h(β|D,D0, a) dβ−p, (4.13)
where β−p is the vector β with the pth element βp removed. We use h(βp|D,D0, a)
to estimate βp and complete the inference.
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For the second hypothesis, we rely on the posterior of γpk, which we derive
from the joint posterior of (βp, βk)
h(βp, βk|D,D0, a) =
∫
· · ·
∫
h(β|D,D0, a) dβ−pk, (4.14)
where β−pk is the vector β with the pth and kth elements βp and βk removed. The
posterior of γpk can be obtained as
h(γpk|D,D0, a) =
∫
h(βp, βp − γpk|D,D0, a) dβp (4.15)
under the transformation βp = βp, γpk = βp − βk. Then we can use h(γpk|D,D0, a)
to estimate γpk and complete the inference.
For the third hypothesis, we first derive the posterior distributions for all βp,
i.e. h(βp|D,D0, a), p = 1, 2, . . . , P − 1, and then calculate the (1 − αP−1) × 100%
HPD intervals of βp and use them to complete the inference. Specifically, the null
hypothesis is retained only when all HPD intervals cover 0.
For a given scientific question concerning the treatment effects, we should
express it as a contrast containing β. We will then derive the posterior of that
contrast based on h(β|D,D0, a) under an appropriate variable transformation. We
will then use that posterior to achieve estimation and inference. This said, none of
the aforementioned posteriors have closed forms, and so we will use an MH algorithm
within Gibbs sampling to draw posterior samples from them for calculation of the
summary statistics of the posterior samples.
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4.4 Algorithms
4.4.1 The K-Nearest Neighbor Algorithm
We used the k-NN algorithm to calculate the symmetric and asymmetric KL diver-
gence (4.7) and (4.8) with the posterior samples of β from f(β|D) and those of β′
from g(β′|D0). We write the posterior samples of β and β′ as {β(1),β(2), . . . ,β(n)}
and {β′(1),β′(2), . . . ,β′(m)}, respectively.
Let ρk(i) be the Euclidean distance between β
(i) and its k-NN in {β(j)}j 6=i.
Specifically, the k-NN of x in {z1, z2, . . . , zn} is zi(k) where i(1), i(2), . . . , i(n) are such
that
||x− zi(1)|| ≤ ||x− zi(2)|| ≤ . . . ≤ ||x− zi(n)||.
The distance from β(i) to its k-NN in {β′(1),β′(2), . . . ,β′(m)} is denoted by
νk(i), then the asymmetric KL divergence D
asym
KL (f ||g) can be calculated as
DˆasymKL (f ||g) =
1
n
n∑
i=1
log(
νk(i)
ρk(i)
) + log(
m
n− 1). (4.16)
Similarly, we let κk(j) be the Euclidean distance between β
′(j) and its k-NN in
{β′(i)}i 6=j, and the Euclidean distance from β′(j) to its k-NN in {β(1),β(2), . . . ,β(n)}
be λk(j), then the symmetric KL divergence D
sym
KL (f ||g) can be calculated as below,
DˆsymKL (f ||g) =
1
n
n∑
i=1
log(
νk(i)
ρk(i)
) + log(
m
n− 1) +
1
m
m∑
j=1
log(
λk(j)
κk(j)
) + log(
n
m− 1). (4.17)
As a result, we have the symmetric and asymmetric discounting fractions as
aˆsym = e−Dˆ
sym
KL (f ||g) = e−Dˆ
sym
KL (g||f).
61
aˆasym = e−Dˆ
asym
KL (f ||g),
4.4.2 The Metropolis Hastings within Gibbs Algorithm
The Gibbs Component of the Hybrid Algorithm
To draw posterior samples of β from the posterior f(β|D), we fit the current data
D with Model (4.2). The joint posterior of β, β0, b, τb and φ is,
f(β, β0, b, τb, φ|D) = f(β, β0, b, τb, φ,D)
f(D)
=
f(Y |β, β0, b, φ)f(β)f(β0)f(b|τb)f(τb)f(φ|ζ)∫ ·· · ∫ f(Y |β, β0, b, φ)f(β)f(β0)f(b|τb)f(τb)f(φ|ζ) dβ dβ0 db dτb dφ
∝ f(Y |β, β0, b, φ)f(β)f(β0)f(b|τb)f(τb)f(φ|ζ)
=
{
I∏
i=1
Ji∏
j=1
exp{Yij(β0 +X
T
i β + bi)− d(β0 +XTi β + bi)
a(φ)
+ c(Yij, φ)}
}
{
P−1∏
p=1
√
τβp
2pi
e−
τβp
2
(βp−µβp )2
}{√
τβ0
2pi
e−
τβ0
2
(β0−µβ0 )2
}{ I∏
i=1
√
τb
2pi
e−
1
2
b2i τb
}
{
νκbb
Γ(κb)
τκb−1b e
−νbτb
}
f(φ|ζ)
∝
{
I∏
i=1
Ji∏
j=1
exp{Yij(β0 +X
T
i β + bi)− d(β0 +XTi β + bi)
a(φ)
+ c(Yij, φ)}
}
{
P−1∏
p=1
e−
τβp
2
(βp−µβp )2
}{
e−
τβ0
2
(β0−µβ0 )2
}{ I∏
i=1
√
τbe
− 1
2
b2i τb
}
{
τκb−1b e
−νbτb} f(φ|ζ),
where Y = (Y11, . . . , Y1J1 , . . . , YI1, . . . , YIJI ). Therefore, the full conditionals of β,β0,
b, τb and φ are
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f(β|D, β0, b, τb, φ)
= f(β|D, β0, b, φ)
=
f(β, β0, b, τb, φ|D)
f(β0, b, τb, φ|D)
=
f(β, β0, b, τb, φ|D)∫ ·· · ∫ f(β, β0, b, τb, φ|D) dβ
=
{∏I
i=1
∏Ji
j=1 exp{Yij(β0+X
T
i β+bi)−d(β0+XTi β+bi)
a(φ)
+ c(Yij, φ)}
}{∏P−1
p=1 e
− τβp
2
(βp−µβp )2
}
∫ ·· · ∫ {∏Ii=1∏Jij=1 exp{Yij(β0+XTi β+bi)−d(β0+XTi β+bi)a(φ) + c(Yij, φ)}}{∏P−1p=1 e− τβp2 (βp−µβp )2} dβ
∝
{
I∏
i=1
Ji∏
j=1
exp{Yij(β0 +X
T
i β + bi)− d(β0 +XTi β + bi)
a(φ)
+ c(Yij, φ)}
}{
P−1∏
p=1
e−
τβp
2
(βp−µβp )2
}
,
f(β0|D,β, b, τb, φ)
= f(β0|D,β, b, φ)
=
f(β, β0, b, τb, φ|D)
f(β, b, τb, φ|D)
=
f(β, β0, b, τb, φ|D)∫
f(β, β0, b, τb, φ|D) dβ0
=
{∏I
i=1
∏Ji
j=1 exp{Yij(β0+X
T
i β+bi)−d(β0+XTi β+bi)
a(φ)
+ c(Yij, φ)}
}{
e−
τβ0
2
(β0−µβ0 )2
}
∫ {∏I
i=1
∏Ji
j=1 exp{Yij(β0+X
T
i β+bi)−d(β0+XTi β+bi)
a(φ)
+ c(Yij, φ)}
}{
e−
τβ0
2
(β0−µβ0 )2
}
dβ0
∝
{
I∏
i=1
Ji∏
j=1
exp{Yij(β0 +X
T
i β + bi)− d(β0 +XTi β + bi)
a(φ)
+ c(Yij, φ)}
}{
e−
τβ0
2
(β0−µβ0 )2
}
,
f(b|D,β, β0, τb, φ)
=
f(β, β0, b, τb, φ|D)
f(β, β0, τb, φ|D)
=
f(β, β0, b, τb, φ|D)∫ ·· · ∫ f(β, β0, b, τb, φ|D) db
=
{∏I
i=1
∏Ji
j=1 exp{Yij(β0+X
T
i β+bi)−d(β0+XTi β+bi)
a(φ)
+ c(Yij, φ)}
}{∏I
i=1
√
τbe
− 1
2
b2i τb
}
∫ {∏I
i=1
∏Ji
j=1 exp{Yij(β0+X
T
i β+bi)−d(β0+XTi β+bi)
a(φ)
+ c(Yij, φ)}
}{∏I
i=1
√
τbe
− 1
2
b2i τb
}
db
∝
{
I∏
i=1
Ji∏
j=1
exp{Yij(β0 +X
T
i β + bi)− d(β0 +XTi β + bi)
a(φ)
+ c(Yij, φ)}
}{
I∏
i=1
√
τbe
− 1
2
b2i τb
}
,
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f(τb|D,β, β0, b, φ)
= f(τb|b)
=
f(β, β0, b, τb, φ|D)
f(β, β0, b, φ|D)
=
f(β, β0, b, τb, φ|D)∫
f(β, β0, b, τb, φ|D) dτb
=
{∏I
i=1
√
τbe
− 1
2
b2i τb
}{
τκb−1b e
−νbτb}∫ {∏I
i=1
√
τbe
− 1
2
b2i τb
}{
τκb−1b e−νbτb
}
dτb
∝
{
I∏
i=1
√
τbe
− 1
2
b2i τb
}{
τκb−1b e
−νbτb}
∼ Gamma(κb + I
2
, νb +
∑I
i b
2
i
2
),
f(φ|D,β, β0, b, τb)
= f(φ|D,β, β0, b)
=
f(β, β0, b, τb, φ|D)
f(β, β0, b, τb|D)
=
f(β, β0, b, τb, φ|D)∫
f(β, β0, b, τb, φ|D) dφ
=
{∏I
i=1
∏Ji
j=1 exp{Yij(β0+X
T
i β+bi)−d(β0+XTi β+bi)
a(φ)
+ c(Yij, φ)}
}
f(φ|ζ)∫ {∏I
i=1
∏Ji
j=1 exp{Yij(β0+X
T
i β+bi)−d(β0+XTi β+bi)
a(φ)
+ c(Yij, φ)}
}
f(φ|ζ) dφ
∝
{
I∏
i=1
Ji∏
j=1
exp{Yij(β0 +X
T
i β + bi)− d(β0 +XTi β + bi)
a(φ)
+ c(Yij, φ)}
}
f(φ|ζ).
Secondly, we fit the historical data D0 with Model (4.6) to draw posterior
samples of β′ from g(β′|D0). The joint posterior distribution of β′,β′0 and φ′ is
64
g(β′, β′0, φ
′|D0) = g(β
′, β′0, φ
′,D0)
g(D0)
=
g(Z|β′, β′0, φ′)g(β′)g(β′0)g(φ′|ζ ′)∫ ·· · ∫ g(Z|β′, β′0, φ′)g(β′)g(β′0)g(φ′|ζ ′) dβ′ dβ′0 dφ′
∝ g(Z|β′, β′0, φ′)g(β′)g(β′0)g(φ′|ζ ′)
=
{ P−1∏
l=1
∫
· · ·
∫
exp{Zl(β
′
0 +X
′T
l β
′)−Nld(β′0 +X ′Tl β′)
a(φ′)
}
exp{
Nl−1∑
i=1
c(Zil, φ
′) + c(Zl −
Nl−1∑
i=1
Zil, φ
′)} dZ1l . . . dZNl−1l
}
{
P−1∏
p=1
√
τβ′p
2pi
e
−
τ
β′p
2
(β′p−µβ′p )
2
}{√
τβ′0
2pi
e
−
τ
β′0
2
(β′0−µβ′0 )
2
}
g(φ′|ζ ′)
∝
{ P−1∏
l=1
∫
· · ·
∫
exp{Zl(β
′
0 +X
′T
l β
′)−Nld(β′0 +X ′Tl β′)
a(φ′)
}
exp{
Nl−1∑
i=1
c(Zil, φ
′) + c(Zl −
Nl−1∑
i=1
Zil, φ
′)} dZ1l . . . dZNl−1l
}
{
P−1∏
p=1
e
−
τ
β′p
2
(β′p−µβ′p )
2
}{
e
−
τ
β′0
2
(β′0−µβ′0 )
2
}
g(φ′|ζ ′),
where Z = (Z0, Z1, . . . , ZP−1). Therefore, the full conditionals of β′, β′0 and φ
′ are
g(β′|D0, β′0, φ′) =
g(β′, β′0, φ
′|D0)
g(β′0, φ′|D0)
=
g(β′, β′0, φ
′|D0)∫ ·· · ∫ g(β′, β′0, φ′|D0) dβ′
∝
{ P−1∏
l=1
∫
· · ·
∫
exp{Zl(β
′
0 +X
′T
l β
′)−Nld(β′0 +X ′Tl β′)
a(φ′)
}
exp{
Nl−1∑
i=1
c(Zil, φ
′) + c(Zl −
Nl−1∑
i=1
Zil, φ
′)} dZ1l . . . dZNl−1l
}{P−1∏
p=1
e
−
τ
β′p
2
(β′p−µβ′p )
2
}
,
65
g(β′0|D0,β′, φ′) =
g(β′, β′0, φ
′|D0)
g(β′, φ′|D0)
=
g(β′, β′0, φ
′|D0)∫
g(β′, β′0, φ′|D0) dβ′0
∝
{ P−1∏
l=1
∫
· · ·
∫
exp{Zl(β
′
0 +X
′T
l β
′)−Nld(β′0 +X ′Tl β′)
a(φ′)
}
exp{
Nl−1∑
i=1
c(Zil, φ
′) + c(Zl −
Nl−1∑
i=1
Zil, φ
′)} dZ1l . . . dZNl−1l
}{
e
−
τ
β′0
2
(β′0−µβ′0 )
2
}
,
g(φ′|D0,β′, β′0) =
g(β′, β′0, φ
′|D0)
g(β′, β′0|D0)
=
g(β′, β′0, φ
′|D0)∫
g(β′, β′0, φ′|D0) dφ′
∝
{ P−1∏
l=1
∫
· · ·
∫
exp{Zl(β
′
0 +X
′T
l β
′)−Nld(β′0 +X ′Tl β′)
a(φ′)
}
exp{
Nl−1∑
i=1
c(Zil, φ
′) + c(Zl −
Nl−1∑
i=1
Zil, φ
′)} dZ1l . . . dZNl−1l
}
g(φ′|ζ ′).
Finally, we perform a power prior analysis (4.12) with both data D and D0
to draw posterior samples of β from h(β|D,D0, a). The augmented posterior distri-
bution of β,β0,b,τb,φ, β
′,β′0,φ
′,ρ,µ and τ is
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h(β, β0, b, τb, φ,β
′, β′0, φ
′,µ, τ ,ρ|D,D0, a)
=
h(β, β0, b, τb, φ,β
′, β′0, φ
′,µ, τ ,ρ,D,D0, a)
h(D,D0, a)
∝ L(β0,β|D, b)f(β0)f(b|τb)f(τb)f(φ|ζ)(L(β′0,β′|D0)ag(β′0)g(φ′|ζ ′)
P−1∏
p=1
{
hp(βp|mp,Λp)hp(µp|ap, Rp)hp(τp|κp, νp)hp(ρp|cp, dp)
}
=
{ I∏
i=1
Ji∏
j=1
exp{Yij(β0 +X
T
i β + bi)− d(β0 +XTi β + bi)
a(φ)
+ c(Yij, φ)}
}{√
τβ0
2pi
e−
τβ0
2
(β0−µβ0 )2
}
{
I∏
i=1
√
τb
2pi
e−
1
2
b2i τb
}{
νκbb
Γ(κb)
τκb−1b e
−νbτb
}
f(φ|ζ)
{ P−1∏
l=1
∫
· · ·
∫
exp{Zl(β
′
0 +X
′T
l β
′)−Nld(β′0 +X ′Tl β′)
a(φ′)
}
exp{
Nl−1∑
i=1
c(Zil, φ
′) + c(Zl −
Nl−1∑
i=1
Zil, φ
′)} dZ1l . . . dZNl−1l
}a{√τβ′0
2pi
e
−
τ
β′0
2
(β′0−µβ′0 )
2
}
g(φ′|ζ ′)
P−1∏
p=1
{
1
2pi
|Λp| 12 e−
(βp−mp)′Λp(βp−mp)
2
√
Rp
2pi
e−
Rp
2
(µp−ap)2 ν
κp
p
Γ(κp)
τκp−1p e
−νpτp ρ
cp−1
p (1− ρp)dp−1
B(cp, dp)
}
∝
{ I∏
i=1
Ji∏
j=1
exp{Yij(β0 +X
T
i β + bi)− d(β0 +XTi β + bi)
a(φ)
+ c(Yij, φ)}
}{
e−
τβ0
2
(β0−µβ0 )2
}
{
I∏
i=1
√
τbe
− 1
2
b2i τb
}{
τκb−1b e
−νbτb} f(φ|ζ){ P−1∏
l=1
∫
· · ·
∫
exp{Zl(β
′
0 +X
′T
l β
′)−Nld(β′0 +X ′Tl β′)
a(φ′)
}
exp{
Nl−1∑
i=1
c(Zil, φ
′) + c(Zl −
Nl−1∑
i=1
Zil, φ
′)} dZ1l . . . dZNl−1l
}a{
e
−
τ
β′0
2
(β′0−µβ′0 )
2
}
g(φ′|ζ ′)
P−1∏
p=1
{
|Λp| 12 e−
(βp−mp)′Λp(βp−mp)
2 e−
Rp
2
(µp−ap)2τκp−1p e
−νpτpρcp−1p (1− ρp)dp−1
}
,
so the full conditionals of β,β0,b,τb,φ,β
′,β′0,φ
′,ρp, µp, τp, p = 1, 2, . . . , P − 1 are
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h(β|D,D0, a, β0, b, τb, φ,β′, β′0, φ′,µ, τ ,ρ)
= h(β|D, β0, b, φ,β′,µ, τ ,ρ)
=
h(β, β0, b, τb, φ,β
′, β′0, φ
′,µ, τ ,ρ|D,D0, a)∫
h(β, β0, b, τb, φ,β
′, β′0, φ′,µ, τ ,ρ|D,D0, a) dβ
∝
{ I∏
i=1
Ji∏
j=1
exp{Yij(β0 +X
T
i β + bi)− d(β0 +XTi β + bi)
a(φ)
+ c(Yij, φ)}
}
P−1∏
p=1
{
|Λp| 12 e−
(βp−mp)′Λp(βp−mp)
2
}
∝
{ I∏
i=1
Ji∏
j=1
exp{Yij(β0 +X
T
i β + bi)− d(β0 +XTi β + bi)
a(φ)
+ c(Yij, φ)}
}
P−1∏
p=1
{
e
− τp
2(1−ρ2p)
{(βp−µp)2−2ρp(βp−µp)(β′p−µp)}
}
,
h(β0|D,D0, a,β, b, τb, φ,β′, β′0, φ′,µ, τ ,ρ)
= h(β0|D,β, b, φ)
=
h(β, β0, b, τb, φ,β
′, β′0, φ
′,µ, τ ,ρ|D,D0, a)∫
h(β, β0, b, τb, φ,β
′, β′0, φ′,µ, τ ,ρ|D,D0, a) dβ0
∝
{ I∏
i=1
Ji∏
j=1
exp{Yij(β0 +X
T
i β + bi)− d(β0 +XTi β + bi)
a(φ)
+ c(Yij, φ)}
}{
e−
τβ0
2
(β0−µβ0 )2
}
,
h(φ|D,D0, a,β, β0, b, τb,β′, β′0, φ′,µ, τ ,ρ)
= h(φ|D,β, β0, b)
=
h(β, β0, b, τb, φ,β
′, β′0, φ
′,µ, τ ,ρ|D,D0, a)∫
h(β, β0, b, τb, φ,β
′, β′0, φ′,µ, τ ,ρ|D,D0, a) dφ
∝
{ I∏
i=1
Ji∏
j=1
exp{Yij(β0 +X
T
i β + bi)− d(β0 +XTi β + bi)
a(φ)
+ c(Yij, φ)}
}
f(φ|ζ),
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h(b|D,D0, a,β, β0, τb, φ,β′, β′0, φ′,µ, τ ,ρ)
= h(b|D,β, β0, τb, φ)
=
h(β, β0, b, τb, φ,β
′, β′0, φ
′,µ, τ ,ρ|D,D0, a)∫
h(β, β0, b, τb, φ,β
′, β′0, φ′,µ, τ ,ρ|D,D0, a) db
∝
{ I∏
i=1
Ji∏
j=1
exp{Yij(β0 +X
T
i β + bi)− d(β0 +XTi β + bi)
a(φ)
+ c(Yij, φ)}
}{ I∏
i=1
√
τbe
− 1
2
b2i τb
}
,
h(τb|D,D0, a,β, β0, b, φ,β′, β′0, φ′,µ, τ ,ρ)
= h(τb|b)
=
h(β, β0, b, τb, φ,β
′, β′0, φ
′,µ, τ ,ρ|D,D0, a)∫
h(β, α, b, τb, φ,β
′, β′0, φ′,µ, τ ,ρ|D,D0, a) dτb
=
{∏I
i=1
√
τbe
− 1
2
b2i τb
}{
τκb−1b e
−νbτb}∫ {∏I
i=1
√
τbe
− 1
2
b2i τb
}{
τκb−1b e−νbτb
}
dτb
∝
{
I∏
i=1
√
τbe
− 1
2
b2i τb
}{
τκb−1b e
−νbτb}
∼ Gamma(κb + I
2
, νb +
∑I
i=1 b
2
i
2
),
h(β′|D,D0, a,β, β0, b, τb, φ, β′0, φ′,µ, τ ,ρ)
= h(β′|D0, a,β, β′0, φ′,µ, τ ,ρ)
=
h(β, β0, b, τb, φ,β
′, β′0, φ
′,µ, τ ,ρ|D,D0, a)∫
h(β, β0, b, τb, φ,β
′, β′0, φ′,µ, τ ,ρ|D,D0, a) dβ′
∝
{ P−1∏
l=1
∫
· · ·
∫
exp{Zl(β
′
0 +X
′T
l β
′)−Nld(β′0 +X ′Tl β′)
a(φ′)
}
exp{
Nl−1∑
i=1
c(Zil, φ
′) + c(Zl −
Nl−1∑
i=1
Zil, φ
′)} dZ1l . . . dZNl−1l
}a P−1∏
p=1
{
|Λp| 12 e−
(βp−mp)′Λp(βp−mp)
2
}
∝
{ P−1∏
l=1
∫
· · ·
∫
exp{Zl(β
′
0 +X
′T
l β
′)−Nld(β′0 +X ′Tl β′)
a(φ′)
}
exp{
Nl−1∑
i=1
c(Zil, φ
′) + c(Zl −
Nl−1∑
i=1
Zil, φ
′)} dZ1l . . . dZNl−1l
}a
P−1∏
p=1
{
e
− τp
2(1−ρ2p)
{(β′p−µp)2−2ρp(βp−µp)(β′p−µp)}
}
,
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h(β′0|D,D0, a,β, β0, b, τb, φ,β′, φ′,µ, τ ,ρ)
= h(β′0|D0, a,β′, φ′)
=
h(β, β0, b, τb, φ,β
′, β′0, φ
′,µ, τ ,ρ|D,D0, a)∫
h(β, β0, b, τb, φ,β
′, β′0, φ′,µ, τ ,ρ|D,D0, a) dβ′0
∝
{ P−1∏
l=1
∫
· · ·
∫
exp{Zl(β
′
0 +X
′T
l β
′)−Nld(β′0 +X ′Tl β′)
a(φ′)
}
exp{
Nl−1∑
i=1
c(Zil, φ
′) + c(Zl −
Nl−1∑
i=1
Zil, φ
′)} dZ1l . . . dZNl−1l
}a{
e
−
τ
β′0
2
(β′0−µβ′0 )
2
}
,
h(φ′|D,D0, a,β, β0, b, τb, φ,β′, β′0,µ, τ ,ρ)
= h(φ′|D0, a,β′, β′0)
=
h(β, β0, b, τb, φ,β
′, β′0, φ
′,µ, τ ,ρ|D,D0, a)∫
h(β, β0, b, τb, φ,β
′, β′0, φ′,µ, τ ,ρ|D,D0, a) dφ′
∝
{ P−1∏
l=1
∫
· · ·
∫
exp{Zl(β
′
0 +X
′T
l β
′)−Nld(β′0 +X ′Tl β′)
a(φ′)
}
exp{
Nl−1∑
i=1
c(Zil, φ
′) + c(Zl −
Nl−1∑
i=1
Zil, φ
′)} dZ1l . . . dZNl−1l
}a
g(φ′|ζ ′),
h(ρp|D,D0, a,β, β0, b, τb, φ,β′, β′0, φ′,µ, τ ,ρ−p)
= h(ρp|βp, β′p, µp, τp)
=
h(β, β0, b, τb, φ,β
′, β′0, φ
′,µ, τ ,ρ|D,D0, a)∫
h(β, β0, b, τb, φ,β
′, β′0, φ′,µ, τ ,ρ|D,D0, a) dρp
=
{
|Λp| 12 e−
(βp−mp)′Λp(βp−mp)
2
}{
ρ
cp−1
p (1− ρp)dp−1
}
∫ {|Λp| 12 e− (βp−mp)′Λp(βp−mp)2 }{ρcp−1p (1− ρp)dp−1} dρp
∝
{
|Λp| 12 e−
(βp−mp)′Λp(βp−mp)
2
}{
ρcp−1p (1− ρp)dp−1
}
∝ ρcp−1p (1− ρp)dp−1e
−τp (βp−µp)
2−2ρp(βp−µp)(β′p−µp)+(β′p−µp)2
2(1−ρ2p) .
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h(µp|D,D0, a,β, β0, b, τb, φ,β′, β′0, φ′,µ−p, τ ,ρ)
= h(µp|βp, β′p, τp, ρp)
=
h(β, β0, b, τb, φ,β
′, β′0, φ
′,µ, τ ,ρ|D,D0, a)∫
h(β, β0, b, τb, φ,β
′, β′0, φ′,µ, τ ,ρ|D,D0, a) dµp
=
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|Λp| 12 e−
(βp−mp)′Λp(βp−mp)
2
}{
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2
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}
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∝ e
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2τp
1 + ρp
+Rp),
h(τp|D,D0, a,β, β0, b, τb, φ,β′, β′0, φ′,µ, τ−p,ρ)
= h(τp|βp, β′p, µp, ρp)
=
h(β, β0, b, τb, φ,β
′, β′0, φ
′,µ, τ ,ρ|D,D0, a)∫
h(β, β0, b, τb, φ,β
′, β′0, φ′,µ, τ ,ρ|D,D0, a) dτp
=
{
|Λp| 12 e−
(βp−mp)′Λp(βp−mp)
2
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τ
κp−1
p e−νpτp
}
∫ {|Λp| 12 e− (βp−mp)′Λp(βp−mp)2 }{τκp−1p e−νpτp} dτp
∝
{
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}{
τκp−1p e
−νpτp}
= τ
κp+
1
2
−1
p e
−τp(νp+ (βp−µp)
2−2ρp(βp−µp)(β′p−µp)+(β′p−µp)2
2(1−ρ2p)
)
∼ Gamma(κp + 1
2
, νp +
(βp − µp)2 − 2ρp(βp − µp)(β′p − µp) + (β′p − µp)2
2(1− ρ2p)
),
The Metropolis Hastings Component of the Hybrid Algorithm
When the Gibbs algorithm is used to draw posterior samples of β from f(β|D),
β′ from g(β′|D0) or β from h(β|D,D0, a), not all of the full conditionals have
closed forms. So we construct a Markov chain with the full conditional as the target
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distribution to get the corresponding posterior samples. This is the MH part of the
hybrid algorithm. We develop a random walk MH algorithm with a t proposal density.
Since the algorithm can be implemented for the parameters in the same way, we write
the MH algorithm in a more general notation.
We write the parameter of interest and the nuisance parameters as θ and
θ′, respectively, and write the data as Dg. Assuming that the full conditional is
k(θ|Dg,θ′), we note that the MH part of the hybrid algorithm for θ can be carried
out as follows.
1. Start with θ0 and set m = 1.
2. Sample θ∗ ∼ t(θm−1, νt), and accept θ∗ with probability
min{1, k(θ
∗|Dg,θ′)
k(θm−1|Dg,θ′)
},
and set θm = θ∗. Otherwise, set θm = θm−1.
3. Increase m by 1 and return to step 2.
Here t(θm−1, νt) is the univariate or multivariate t distribution with θ
m−1 and
νt as the location and degree of freedom, depending on whether θ is a random variable
or vector. With this hybrid algorithm, the posterior samples of θ are drawn from its
posterior k(θ|Dg).
4.5 Simulation Studies
4.5.1 Simulation Settings and Data Generation
We conducted a simulation study to examine the performance of this power prior
method in cluster randomized trials with (1) two arms in normal data; (2) two arms
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in count data; and (3) three arms in binary data. The trials were assumed to be
balanced in treatment group size. For two-arm trials with normal data, the model
for generating the current data D = {(X1i, Yij) : i = 1, 2, . . . , I, j = 1, 2, . . . , J} was
Yij ∼ Normal(µi, τ1), µi = β0 + β1X1i + bi,bi ∼ Normal(0, τb), and the model for
generating the historical data D0 = {(X ′1l, Zl) : l = 0, 1} was Zl ∼ Normal(Nµl, τ2N ),
µl = β
′
0 + β
′
1X
′
1l, where half of X1i is 0 for placebo arm and the other half is 1 for
treatment arm. X ′1l = 0 when l = 0 for placebo arm and it is equal to 1 when l = 1
for treatment arm.
For two-arm trials with count data, the current trial data model, however, was
Yij ∼ Poisson(λi), log(λi) = β0+β1X1i+bi, bi ∼ Normal(0, τb), and the historical trial
data model was Zl ∼ Poisson(Nλl),log(λl) = β′0 + β′1X ′1l. X1i and X ′1l take the same
values as those in two arm trials with normal data. For three-arm trials with binary
data, the current trial data D = {(X1i, X2i, Yij) : i = 1, 2, . . . , I, j = 1, 2, . . . , J}
was generated by the model Yij ∼ Bernoulli(pi), logit(pi) = β0 + β1X1i + β2X2i + bi,
bi ∼ Normal(0, τb), and the historical trial data D0 = {(X ′1l, X ′2l, Zl) : l = 0, 1, 2} was
generated by the model Zl ∼ Binomial(N, ql), logit(ql) = β′0 + β′1X ′1l + β′2X ′2l. The
first third of (X1i, X2i) is (0, 0) for the placebo arm, the second third of (X1i, X2i) is
(1, 0) for the first treatment arm, and the remaining is (0, 1) for the second treatment
arm. Additionally, (X ′1l, X
′
2l) = (0, 0) when l = 0 for placebo arm, (1, 0) when l = 1
for the first treatment arm and (0, 1) when l = 2 for the second treatment arm.
In each of these three cases, simulation studies were carried out to investigate
the effects of the treatment effect (β1, β
′
1) in two arm trials and (β1, β2, β
′
1, β
′
2) in three
arm trials, the historical arm size N , the total cluster number I, cluster size J , the
ICC ρ in current trial. For normal data, ρ = τb
τb+τ1
, and for count data, the ICC
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changes between different arms (Stryhn et al., 2006). Let the ICC be ρ+ and ρ− for
treatment arm and placebo arm, respectively, then we could calculate them as
ρ+ =
exp(2 ∗ (β0 + β1 + 1τb ))− exp(2 ∗ (β0 + β1) + 1τb )
exp(2 ∗ (β0 + β1 + 1τb ))− exp(2 ∗ (β0 + β1) + 1τb ) + exp(β0 + β1 + 12τb )
and,
ρ− =
exp(2 ∗ (β0 + 1τb ))− exp(2 ∗ β0 + 1τb )
exp(2 ∗ (β0 + 1τb ))− exp(2 ∗ β0 + 1τb ) + exp(β0 + 12τb )
.
For binary data, ρ = 1
1+pi
2
3
τb
. For the purpose of illustration, we used the study of
the effect of treatment effect (β1, β
′
1) as an example in this section. The other results
about the effect of N , I, J and ρ could be required from the authors once requested.
The settings of the current trial and historical trial were given in Tables 4.1 and 4.2,
respectively.
For each parameter setting in Tables 4.1 and 4.2, 1, 000 data replicates were
simulated from the corresponding model, and each data replicate was analyzed with
the power prior method under four different discounting parameters, that is, 0, 1, asym
and aasym. The posterior median, SD and the 95% HPD interval of β1 were computed.
Additionally, the posterior median and SD of β2, the 95% HPD interval of β1 − β2
and the 97.5% HPD intervals of β1 and β2 were calculated as well for three-arm trials.
The 95% HPD interval was used to test the null hypothesis H0 : E(β1|D,D0) = 0
or H0 : E(β1 − β2|D,D0) = 0, and the 97.5% HPD interval was used to test the
null hypothesis H0 : E(β1|D,D0) = E(β2|D,D0) = 0. By averaging the 1, 000 sets
of analytical results, we could calculate the estimate of the posterior median, SD,
relative bias, rMSE of β1 (and β2 and β1 − β2 for three-arm trials as well), and the
average length, CP and RP of the HPD intervals. The RP was type I error rate
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when β1 = 0 and power otherwise for H0 : E(β1|D,D0) = 0, and β1 − β2 = 0 for
H0 : E(β1−β2|D,D0) = 0, and β1 = β2 = 0 for H0 : E(β1|D,D0) = E(β2|D,D0) = 0.
To calculate the KL divergence based discounting parameters, separate data analyses
of current and historical trials were done under non-informative priors within Bayesian
framework. The MH within Gibbs algorithm was used to complete the computation,
and a Markov Chain of length 2, 500 was run with the first 1, 500 samples discarded
and the thinning rate being 5. In the power prior data analysis, however, a Markov
Chain of length 5, 000 was run with the first 2, 500 samples discarded and the thinning
rate being 5. In both scenarios, a t proposal density was used, and its degree of
freedom νt was set to be 3. The MCMC convergence was diagnosed with the trace
plots. To end this section, we would point out that, in these three cases, we also
developed similar simulation based algorithm in the design of cluster randomized
trials as before, and simulation studies were done to determine the sample size. These
results could be required from the authors once requested.
4.5.2 Simulation Results
For illustrative purpose, we reported the effect of the treatment effect (β1, β
′
1) on the
discounting fraction, SD, rMSE and type I error rate and power in the three different
cases. All results were summarized in Figures 4.1− 4.5.
Figure 4.1 shows the results from the two-arm trials with normal data. From
the animation plot of discounting fraction, we see that the estimate of the symmetric
and asymmetric KL divergence based discounting fractions, asym and aasym, would
increase as the historical treatment effect β′1 got closer to the current one β1. As
asym and aasym became larger, more historical information similar to the current one
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were borrowed, and therefore, the SD and rMSE would become smaller, which was
illustrated in the animation plots of SD and rMSE. The animation plot of power
shows that it would increase as more similar historical information were borrowed
and that it would decrease otherwise. The opposite trend was observed for type I
error rate from its animation plot.
Figures 4.2 − 4.3 demonstrate the same information about the discounting
fraction, SD, rMSE and type I error rate and power for the null hypothesis H0 :
E(β1|D,D0) = 0 in two-arm trials with count data and three-arm trials with binary
data. Furthermore, in three-arm trials with binary data, we fixed β2 = β
′
2 = log(1) =
0, and we investigated the effect of β′1−β′2 = β′1 on the SD and rMSE of β1−β2 = β1
and the type I error rate and power for the null hypothesis H0 : E(β1−β2|D,D0) = 0
with Figure 4.4. The same message could be read from this Figure as those from
Figures 4.1 − 4.3. Finally, we used the 97.5% HPD intervals of β1 and β2 to do
the simultaneous test of H0 : E(β1|D,D0) = E(β2|D,D0) = 0, and the animation
plot of the type I error rate and power was given in Figure 4.5. As a by-product, the
animation plots of SD and rMSE of β2 were also given in Figure 4.5. From this figure,
we see the SD and rMSE of β2 decreased as more similar historical information was
borrowed (see the animation plot of discounting fraction in Figure 4.3). As similar
historical information was borrowed, the power would increase and the type I error
rate would decrease.
4.6 Discussion
In this chapter, we extended our power prior approach to multi-arm cluster ran-
domized trial with outcome from exponential family distributions, and we used well-
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designed simulation studies to evaluate its performance in three different situations,
including two-arm trial with normal outcome, two-arm trial with count outcome and
three-arm trial with binary outcome. All simulation results showed that our power
prior method was useful in the design and analysis of cluster randomized trial in these
situations. After borrowing historical information with this power prior method, we
could expect to increase the power by 10 percent under some conditions, and at the
same time,we could control the type I error rate. This meant fewer samples would be
needed to achieve a pre-specified power with the type I error rate controlled.
In the Simulation Studies section, we used the animation plots to present the
results. This was a very useful way to visualize high dimensional data. Compared
to traditional plots, the animation plots could help the readers recognize the key
findings behind the results quickly and save space as well. This method was expected
to have some values in applications, however, some of its users, such as trialists or
health care practitioners, might have little statistical and programming knowledge.
Therefore it was necessary to develop a computational tool for this method so that
the users could use it to design and analyze cluster randomized trial conveniently.
For example, they might only need to upload the data onto the computational tool
and click certain buttons to get the results. This computational tool was expected
to have three functionalities, including (1) analyzing a cluster randomized trial with
a historical trial data; (2) designing a cluster randomized trial given a historical trial
data; and (3) visualizing high dimensional data with animation plots. Since our
program was developed with R, we intended to develop the computational tool as a
R package, and submit it onto Github or CRAN for users to download and use it.
This topic would be covered in the next chapter.
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Table 4.1: Current trial setting with different types of data and numbers of arm
Data type Arm number I J β0 β1 β2 τb τ1
Normal 2 10 10 −0.1 0, 1, 1.5, . . . , 3 − 1 1
Count 2 20 20 −0.1 log(1), log(1.2), . . . , log(2) − 4 −
Binary 3 30 20 −0.1 log(1), log(4) log(1) 1 −
Table 4.2: Historical trial setting with different types of data and numbers of arm
Data type Arm number N β′0 β
′
1 β
′
2 τ2
Normal 2 200 0.1 0, 1, 1.5, . . . , 3 − 1
Count 2 200 0.1 log(1), log(1.2), . . . , log(2) − −
Binary 3 200 0.1 log(1), log(2), . . . , log(6) log(1) −
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Figure 4.1: In two-arm trial with normal data, the effect of the historical treatment effect
β′1 on the discounting fraction, SD, rMSE, type I error rate and power where the total
number of cluster I = 10,the cluster size J = 10, and the ICC ρ = 0.5 in current trial and
the arm size N = 200 in historical trial. Type I error rate and power correspond to β1 = 0
and β1 = 1, 1.5, 2, 2.5, 3.
79
Figure 4.2: In two-arm trial with count data, the effect of the historical treatment effect
β′1 on the discounting fraction, SD, rMSE, type I error rate and power where the total
number of cluster I = 20,the cluster size J = 20 in current trial and the arm size N =
200 in historical trial. Type I error rate and power correspond to β1 = log(1) = 0 and
β1 = log(1.2), log(1.4), log(1.6), log(1.8), log(2) ≈ 0.182, 0.336, 0.470, 0.588, 0.693. The ICC
are ρ+ = 0.226, 0.259, 0.290, 0.318, 0.344, 0.368 for the treatment arm and ρ− = 0.226 for
the placebo arm where β1 = 0, 0.182, 0.336, 0.470, 0.588, 0.693.
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Figure 4.3: In three-arm trial with binary data, the effect of the historical treatment effect
β′1 on the discounting fraction, SD and rMSE of β1, type I error rate and power where the
total number of cluster I = 30,the cluster size J = 20, and the ICC ρ = 0.233 in current
trial and the arm size N = 200 in historical trial. Type I error rate and power correspond
to β1 = log(1) = 0 and β1 = log(4) ≈ 1.386.
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Figure 4.4: In three-arm trial with binary data, the effect of the historical treatment effect
β′1 on the discounting fraction, SD and rMSE of β1− β2, type I error rate and power where
the total number of cluster I = 30,the cluster size J = 20, and the ICC ρ = 0.233 in current
trial and the arm size N = 200 in historical trial. Type I error rate and power correspond
to β1 = log(1) = 0 and β1 = log(4) ≈ 1.386.
82
Figure 4.5: In three-arm trial with binary data, the effect of the historical treatment effect
β′1 on the discounting fraction, SD and rMSE of β2, type I error rate and power where the
total number of cluster I = 30,the cluster size J = 20, and the ICC ρ = 0.233 in current
trial and the arm size N = 200 in historical trial. Type I error rate and power correspond
to β1 = log(1) = 0 and β1 = log(4) ≈ 1.386.
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Chapter 5
Computational Tools
In this chapter, we briefly describe our effort in the development of computational
tools for the proposed methods. The end product is an R package, containing all
necessary functions for the implementation of the described methods. At the time of
completion of this dissertation, the main functions of the package have been developed
and tested, but have not been released for public use.
5.1 The R Platform
Among the most widely used statistical computing platforms, R has two distinct
advantages: (1) free availability of statistical computing, and (2) accommodation
of user-created packages. This has led to a highly engaged and active development
community. In R, packages are the basic units of collections of reusable R functions,
supplemented by documentation and real data illustrations. In this dissertation, all
of the computational methods discussed in the first four chapters are programmed
into modularized R functions and organized into a comprehensive R package. The
package allows analysts and trialists to perform Bayesian power prior analysis, as well
as estimate the sample size and power for design of new studies.
A minimal R package contains three components, an “R/” directory, a DE-
SCRIPTION file, and a NAMESPACE file (Wickham, 2015). Currently, the com-
ponents may be created in a menu-driven way using Rstudio. The “R/” directory
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is used to store individual R scripts, the DESCRIPTION file describes the uses and
functionality of the package, and the NAMESPACE file defines which functions it
avails to other packages and which functions it requires from other packages. There
are usually additional tasks for completing the development of a package. For ex-
ample, a “data/” directory could be created to store example data, for illustration
purposes. R objects/functions, including example data, are typically documented
through roxygen2, a LATEX utility for R package documentation. In addition, vignette
files may be created by using Rmarkdown and knitr. Vignettes are sometimes referred
to a long form documentation, and provide a more detailed overview of the methods
and examples of analyses.
5.2 Package overview
We developed an R package, tentatively named pprincrt, to cover the methods de-
scribed in the previous chapters. Because the package is still being tested and has not
been made public, the package and function names are subject to further changes.
The package has two main functions, pprmodelBUGS() and SimPower(). The
former does the Bayesian power prior analysis for cluster randomized trials, and the
latter does power calculation through simulation. The functions are able to incorpo-
rate historical trial information in both data analysis and trial design. Additionally,
the package provides two utility functions: print.pprMod(), which prints model fit-
ting results in an easy to read format, and AniPlot() for animated presentation of
estimated power and type 1 error rates.
In the following subsections, we summarize the main features of the functions.
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5.2.1 Function pprmodelBUGS()
The main utility of function pprmodelBUGS() is to perform the Bayesian power prior
analysis. it executes a series of tasks “under the hood”, outlined in order of imple-
mentation below,
• Write the file cmodelfile.txt into the file directory. It is a BUGS script of the
GLMM model for the current trial data.
• Use function bugs() in the R2OpenBUGS package to call OpenBUGS from R
and to analyze the current trial data with the model in cmodelfile.txt through
batch mode (Spiegelhalter et al., 2007).
• Write the file hmodelfile.txt into the file directory. It is a BUGS script of the
GLM model for the historical trial data.
• Use function bugs() in the R2OpenBUGS package to call OpenBUGS from R
and to analyze the historical trial data with the model in hmodelfile.txt through
batch mode.
• Write file pprmodelfile.txt into the file directory. It is a BUGS script for power
prior analysis model for both current and historical trial data.
In function pprmodelBUGS(), the file directory is set to be tempdir() by de-
fault, but the users may change this through the argument file.dir. All files are
removed after OpenBUGS is done when the argument file.rm is set to TRUE. How-
ever, the default value is set to FALSE. For the current trial, the data are input
through the argument cData, while the analytical model is specified by the argument
cForm. cData is a data frame, and cForm is a formula object. The variable names
in cData must be the same as those in cForm. Besides, hData and hForm are similar
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arguments to cData and cForm, but for data input and model specification of the
historical trial.
The current package runs on the Window platform. The OpenBUGS directory
could be specified by users through the argument OpenBUGS.dir, which is the direc-
tory where the OpenBUGS software is installed. By default, it is set to be NULL,
which means that the most recent OpenBUGS version registered in the Windows
registry will be used. The pseudo random number generator in OpenBUGS has 14
different internal states. Each state is 1012 draws apart to avoid overlap in the pseudo
random number sequences (Spiegelhalter et al., 2007). The state can be pre-specified
through the argument OpenBUGS.seed by setting its value to be an integer between
1 and 14. By default, it is set to be 1.
In function pprmodelBUGS(), one MCMC chain of length 2, 000 is generated.
We discard the first half of the generated values and we do not use thinning. The
user may change the default values for the number of the chain, the number of itera-
tion, the number of burn-in, and the thinning parameter through arguments nchain,
niter,nburnin,nthin, respectively. Two different discounting methods are allowed in
the package: by the symmetric and asymmetric Kullback-Leibler divergence based
discounting parameters, or by an expert proposed proportion (between 0 and 1). The
discounting method is specified by the argument weight.
Function pprmodelBUGS() returns an S3 class object pprMod containing the
posterior samples of the treatment effect, which can be further processed with the
coda package. In addition, the object contains summaries of the posterior samples,
including posterior median, standard deviation, and the highest posterior density
(HPD) interval. The credible level of the HPD interval is specified by argument
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cover.level. An estimate of the discounting parameter is also included in the object.
Convergence diagnostic statistics are also presented, including trace plot, and the
Gelman-Rubin statistic and related plots if two or more MCMC chains are run. All
diagnostic plots are contained in file graphics.pdf under the directory specified by the
argument file.dir.
5.2.2 Function SimPower()
Function SimPower() is used to determine the sample size in designing a new clus-
ter randomized trial with the proposed method given a historical data or a specific
historical trial parameter setting. It may also be used to assess the power of the
proposed method under a pre-specified parameter setting for both current and his-
torical trials. The desired result is specified by argument to.do.option. It takes value
real SSD, sim SSD or sim power for the three aforementioned aims, respectively.
When argument to.do.option takes value real SSD, function SimPower() executes a
series of tasks “under the hood”, outlined in order of implementation below,
• Identify the pre-specified historical trial data.
• Generate multiple curren trial data replicates under an experimental sample
size.
• Analyze each current trial data with power prior method by borrowing infor-
mation from that historical trial data, and output the HPD interval of the
treatment effect.
• Use the HPD interval to make a decision whether to reject the null hypothesis
of non-significant treatment effect.
• Report the proportion of rejection among the decisions as power.
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If the power returned by function SimPower() is not the target one, then we
should try another sample size and repeat the process above with function SimPower()
until the target power is obtained, and then we could report the corresponding sam-
ple size to people. When argument to.do.option takes value sim SSD, function Sim-
Power() works similarly. The only difference is, in the first step, we should generate
one historical trial data with the pre-specified historical trial parameter setting, in-
stead. When argument to.do.option takes value sim power, the first three steps are
changed to the following two steps,
• Generate multiple pairs of current and historical data replicates under the pre-
specified current and historical trial setting.
• For each pair of data replicates, analyze the current trial data with power prior
method by borrowing information from the historical trial data, and output the
HPD interval of the treatment effect.
In this case, the power returned by function SimPower() is reported to people,
directly.
As shown above, multiple replicates of current trial data or historical trial data
might be generated. The number of data replicates is specified by argument Rep. The
arguments cRdmSeed.init and hRdmSeed.init are used to specify the random seeds
for the generation of the first current trial data and the first historical trial data,
respectively. Both random seeds increase by 1 for each of the following trial data. In
concept, the computations on different data replicates are similar and independent, so
they could be done on different cores of the same computer simultaneously, thereby
reducing the computational time. Therefore, we allow parallel computing via the
foreach package in this function.
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Multiple files will be yielded in the file directory as a result of the computation
on each data replicate, such as ’hmodelfile.txt’, ’cmodelfile.txt’, ’pprmodelfile.txt’ and
’graphics.pdf ’. For the concern of space, all these files are removed by default after
the computation is done. This default value could be changed by setting the argu-
ment file.rm=FALSE. Similar to function pprmodelBUGS(), the same arguments are
provided in function SimPower() to specify the OpenBUGS directory, the MCMC
chain features, the discounting parameter and the HPD interval. Additionally, when
to.do.option takes value real SSD, the historical trial data should be specified in the
format of data frame through the argument hData, and the variable names in the data
frame should be the same as those specified in the arguments hTrtVar, hOutcomeVar
and hSumVar. When to.do.option takes value sim SSD or sim power, the historical
trial parameter setting should be specified in the format of list through the argument
hSet, and the variable names in the list should be the same as those specified in the
arguments hNarmVar, hNpat.armVar, hWthVar, hTrtVecVar. Across the three aims,
the current trial parameter setting should be specified in the format of list through
the argument cSet, and the variable names in the list should be the same as those
specified in the arguments cNarmVar, cNcluster.armVar, cNpat.clusterVar, cBtwVar,
cWthVar, cTrtVecVar.
To facilitate the output of computational results, we developed two utility
functions print.pprMod() and AniPlot(). The first function, print.pprMod() prints the
summary statistics of posterior samples, and the second function produces animation
plots, shown in the previous chapters.
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5.2.3 Example 1: HPV vaccine reminder
We consider the HPV vaccine reminder trial sponsored by Merck pharmaceutical as
the current trial. The outcome of interest is vaccine uptake. The trial has been
described in detail in previous chapters. The structure of the data is shown in Table
5.1. On the other hand, We used the trial by Szilagyi et al. (2011) as the source of
historical data. As described before, a total of 2, 139 girls, aged 11 − 15 years, were
recruited and randomized to two different arms. The data are summarized in Table
5.2. These two data were used to illustrate how to use the functions pprmodelBUGS(),
SimPower() and print.pprMod(). The users can refer to the vignette file of this
package for details.
5.2.4 Example 2: Animation data
The animation data is a non-real data for the illustration purpose of the function
AniPlot(). It has four different variables, including the group variable, frame variable
and X-axis and Y-axis variables. The data has 72 observations, and the group and
frame variables have 2 and 6 unique values, respectively. The users can get more
detailed information about the data and how to apply the function AniPlot() to it to
create animation plot by reading the vignette file of this package.
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Table 5.1: Merck HPV vaccine reminder trial
Intervention Physician ID Number of subjects Number of subjects taking vaccine
0 5 14 10
0 13 22 5
0 15 50 22
0 17 11 4
0 19 20 16
0 21 15 8
0 24 10 4
0 25 23 16
0 26 3 1
0 27 55 14
0 28 2 1
1 1 7 7
1 2 24 19
1 3 16 12
1 4 9 2
1 6 1 1
1 7 12 7
1 8 11 9
1 9 16 12
1 10 45 11
1 11 37 33
1 12 12 8
1 14 2 1
1 16 22 10
1 18 2 2
1 20 7 3
1 22 19 13
1 23 8 6
Table 5.2: Szilagyi HPV vaccine reminder trial
Intervention Number of subjects Number of subjects taking vaccine
0 1055 453
1 1084 634
92
BIBLIOGRAPHY
Berger, J. O. (2013). Statistical decision theory and Bayesian analysis. Springer
Science & Business Media.
Beygelzimer, A., S. Kakadet, J. Langford, S. Arya, D. Mount, and S. Li (2013). Fnn:
fast nearest neighbor search algorithms and applications. r package version 1.1.
Brian, N. (2010). Bayesian analysis using power priors with application to pediatric
quality of care. Journal of Biometrics & Biostatistics .
Browne, W. J., D. Draper, et al. (2006). A comparison of bayesian and likelihood-
based methods for fitting multilevel models. Bayesian analysis 1 (3), 473–514.
Campbell, M. (2000). Cluster randomized trials in general (family) practice research.
Statistical Methods in Medical Research 9 (2), 81–94.
Campbell, M., A. Donner, and N. Klar (2007). Developments in cluster randomized
trials and statistics in medicine. Statistics in medicine 26 (1), 2–19.
Carlin, J. B. (1992). Meta-analysis for 2× 2 tables: A bayesian approach. Statistics
in medicine 11 (2), 141–158.
Chen, M.-H., J. G. Ibrahim, et al. (2006). The relationship between the power prior
and hierarchical models. Bayesian Analysis 1 (3), 551–574.
Chen, M.-H., J. G. Ibrahim, H. Amy Xia, T. Liu, and V. Hennessey (2014). Bayesian
sequential meta-analysis design in evaluating cardiovascular risk in a new antidia-
betic drug development program. Statistics in medicine 33 (9), 1600–1618.
93
Chen, M.-H., J. G. Ibrahim, P. Lam, A. Yu, and Y. Zhang (2011). Bayesian design
of noninferiority trials for medical devices using historical data. Biometrics 67 (3),
1163–1170.
Chen, M.-H., J. G. Ibrahim, and Q.-M. Shao (2000). Power prior distributions for
generalized linear models. Journal of Statistical Planning and Inference 84 (1),
121–137.
Chen, M.-H., J. G. Ibrahim, D. Zeng, K. Hu, and C. Jia (2014). Bayesian design
of superiority clinical trials for recurrent events data with applications to bleeding
and transfusion events in myelodyplastic syndrome. Biometrics 70 (4), 1003–1013.
Chen, M.-H., A. K. Manatunga, and C. J. Williams (1998). Heritability estimates
from human twin data by incorporating historical prior information. Biometrics ,
1348–1362.
Chib, S. and B. P. Carlin (1999). On mcmc sampling in hierarchical longitudinal
models. Statistics and Computing 9 (1), 17–26.
Clark, A. B. and M. O. Bachmann (2010). Bayesian methods of analysis for cluster
randomized trials with count outcome data. Statistics in medicine 29 (2), 199–209.
Congdon, P. (2007). Bayesian statistical modelling, Volume 704. John Wiley & Sons.
Darlington, G. A. and A. Donner (2007). Meta-analysis of community-based cluster
randomization trials with binary outcomes. Clinical Trials 4 (5), 491–498.
De Santis, F. (2006). Power priors and their use in clinical trials. The American
Statistician 60 (2), 122–129.
94
De Santis, F. (2007). Using historical data for bayesian sample size determination.
Journal of the Royal Statistical Society: Series A (Statistics in Society) 170 (1),
95–113.
Donner, A. (1992). Sample size requirements for stratified cluster randomization
designs. Statistics in medicine 11 (6), 743–750.
Donner, A. (1998). Some aspects of the design and analysis of cluster randomization
trials. Journal of the Royal Statistical Society: Series C (Applied Statistics) 47 (1),
95–113.
Donner, A. and N. Klar (1994). Cluster randomization trials in epidemiology: theory
and application. Journal of Statistical Planning and Inference 42 (1-2), 37–56.
Donner, A. and N. Klar (2000). Design and analysis of cluster randomization trials
in health research.
Donner, A. and N. Klar (2002). Issues in the meta-analysis of cluster randomized
trials. Statistics in medicine 21 (19), 2971–2980.
Donner, A., G. Piaggio, and J. Villar (2001). Statistical methods for the meta-analysis
of cluster randomization trials. Statistical Methods in Medical Research 10 (5), 325–
338.
Donner, A., G. Piaggio, and J. Villar (2003). Meta-analyses of cluster randomization
trials power considerations. Evaluation & the health professions 26 (3), 340–351.
95
Duan, Y. (2005). A modified bayesian power prior approach with applications in
water quality evaluation. Ph. D. thesis, Virginia Polytechnic Institute and State
University.
Duan, Y., K. Ye, and E. P. Smith (2006). Evaluating water quality using power priors
to incorporate historical information. Environmetrics 17 (1), 95–106.
Gamerman, D. (1997). Sampling from the posterior distribution in generalized linear
mixed models. Statistics and Computing 7 (1), 57–68.
Gelman, A. et al. (2006). Prior distributions for variance parameters in hierarchical
models (comment on article by browne and draper). Bayesian analysis 1 (3), 515–
534.
Goodman, S. N. and J. T. Sladky (2005). A bayesian approach to randomized con-
trolled trials in children utilizing information from adults: the case of guillain-barre.
Clinical Trials 2 (4), 305–310.
Guyatt, G. H., D. L. Sackett, J. C. Sinclair, R. Hayward, D. J. Cook, R. J. Cook,
E. Bass, H. Gerstein, B. Haynes, A. Holbrook, et al. (1995). Users’ guides to
the medical literature: Ix. a method for grading health care recommendations.
Jama 274 (22), 1800–1804.
Hampson, L. V., J. Whitehead, D. Eleftheriou, and P. Brogan (2014). Bayesian
methods for the design and interpretation of clinical trials in very rare diseases.
Statistics in medicine 33 (24), 4186–4201.
96
Hemming, K., A. J. Girling, A. J. Sitch, J. Marsh, and R. J. Lilford (2011). Sample
size calculations for cluster randomised controlled trials with a fixed number of
clusters. BMC medical research methodology 11 (1), 1.
Hobbs, B. P. and B. P. Carlin (2007). Practical bayesian design and analysis for drug
and device clinical trials. Journal of biopharmaceutical statistics 18 (1), 54–80.
Hobbs, B. P., B. P. Carlin, S. J. Mandrekar, and D. J. Sargent (2011). Hierarchi-
cal commensurate and power prior models for adaptive incorporation of historical
information in clinical trials. Biometrics 67 (3), 1047–1056.
Hobbs, B. P., D. J. Sargent, and B. P. Carlin (2012). Commensurate priors for
incorporating historical information in clinical trials using general and generalized
linear models. Bayesian analysis (Online) 7 (3), 639.
Hsu, J. (1996). Multiple comparisons: theory and methods. CRC Press.
Ibrahim, J. G. and M.-H. Chen (2000). Power prior distributions for regression models.
Statistical Science, 46–60.
Ibrahim, J. G., M.-H. Chen, Y. Gwon, and F. Chen (2015). The power prior: theory
and applications. Statistics in medicine 34 (28), 3724–3749.
Ibrahim, J. G., M.-H. Chen, H. A. Xia, and T. Liu (2012). Bayesian meta-
experimental design: Evaluating cardiovascular risk in new antidiabetic therapies
to treat type 2 diabetes. Biometrics 68 (2), 578–586.
Kerry, S. M. and J. M. Bland (1998). Statistics notes: Sample size in cluster ran-
domisation. Bmj 316 (7130), 549.
97
Kong, S.-H., C. W. Ahn, and S.-H. Jung (2003). Sample size calculation for di-
chotomous outcomes in cluster randomization trials with varying cluster size. Drug
information journal 37 (1), 109–114.
Laopaiboon, M. (2003). Meta-analyses involving cluster randomization trials: a
review of published literature in health care. Statistical methods in medical re-
search 12 (6), 515–530.
Lunn, D., D. Spiegelhalter, A. Thomas, and N. Best (2009). The bugs project:
Evolution, critique and future directions. Statistics in medicine 28 (25), 3049–3067.
Manatunga, A. K., M. G. Hudgens, and S. Chen (2001). Sample size estimation in
cluster randomized studies with varying cluster size. Biometrical Journal 43 (1),
75–86.
Matteucci, M. and B. P. Veldkamp (2015). The approach of power priors for ability
estimation in irt models. Quality & Quantity 49 (3), 917–926.
Pezeshk, H. (2003). Bayesian techniques for sample size determination in clinical
trials: a short review. Statistical Methods in Medical Research 12 (6), 489–504.
Rietbergen, C., I. Klugkist, K. J. Janssen, K. G. Moons, and H. J. Hoijtink (2011).
Incorporation of historical data in the analysis of randomized therapeutic trials.
Contemporary clinical trials 32 (6), 848–855.
Robert, C. and G. Casella (2009). Introducing Monte Carlo Methods with R. Springer
Science & Business Media.
98
Rotondi, M. A. and A. Donner (2009). Sample size estimation in cluster random-
ized educational trials: An empirical bayes approach. Journal of Educational and
Behavioral Statistics 34 (2), 229–237.
Schoenfeld, D. A., H. Zheng, and D. M. Finkelstein (2009). Bayesian design using
adult data to augment pediatric trials. Clinical Trials 6 (4), 297–304.
Shao, K. (2012). A comparison of three methods for integrating historical information
for bayesian model averaged benchmark dose estimation. Environmental toxicology
and pharmacology 34 (2), 288–296.
Shuster, J. J., L. S. Jones, and D. A. Salmon (2007). Fixed vs random effects meta-
analysis in rare event studies: The rosiglitazone link with myocardial infarction
and cardiac death. Statistics in medicine 26 (24), 4375–4385.
Spiegelhalter, D., A. Thomas, N. Best, and D. Lunn (2007). Openbugs user manual,
version 3.0. 2. MRC Biostatistics Unit, Cambridge.
Spiegelhalter, D. J. (2001). Bayesian methods for cluster randomized trials with
continuous responses. Statistics in medicine 20 (3), 435–452.
Stamey, J. D., F. Natanegara, and J. W. Seaman Jr (2013). Bayesian sample size
determination for a clinical trial with correlated continuous and binary outcomes.
Journal of biopharmaceutical statistics 23 (4), 790–803.
Stryhn, H., J. Sanchez, P. Morley, C. Booker, and I. Dohoo (2006). Interpretation of
variance parameters in multilevel poisson regression models. In Proceedings of the
11th International Symposium on Veterinary Epidemiology and Economics.
99
Szilagyi, P. G., S. G. Humiston, S. Gallivan, C. Albertin, M. Sandler, and A. Blumkin
(2011). Effectiveness of a citywide patient immunization navigator program on
improving adolescent immunizations and preventive care visit rates. Archives of
pediatrics & adolescent medicine 165 (6), 547–553.
Turner, R. M., R. Z. Omar, and S. G. Thompson (2001). Bayesian methods of
analysis for cluster randomized trials with binary outcome data. Statistics in
medicine 20 (3), 453–472.
Turner, R. M., S. G. Thompson, and D. J. Spiegelhalter (2005). Prior distributions
for the intracluster correlation coefficient, based on multiple previous estimates,
and their application in cluster randomized trials. Clinical Trials 2 (2), 108–118.
Turner, R. M., A. Toby Prevost, and S. G. Thompson (2004). Allowing for imprecision
of the intracluster correlation coefficient in the design of cluster randomized trials.
Statistics in medicine 23 (8), 1195–1214.
Viele, K., S. Berry, B. Neuenschwander, B. Amzal, F. Chen, N. Enas, B. Hobbs, J. G.
Ibrahim, N. Kinnersley, S. Lindborg, et al. (2014). Use of historical control data for
assessing treatment effects in clinical trials. Pharmaceutical statistics 13 (1), 41–54.
Wang, F. and A. E. Gelfand (2002). A simulation-based approach to bayesian sample
size determination for performance under a given model and for separating models.
Statistical Science, 193–208.
Wang, Q., S. R. Kulkarni, and S. Verdu (2009). Divergence estimation for multidimen-
sional densities via-nearest-neighbor distances. IEEE Transactions on Information
Theory 55 (5), 2392–2405.
100
Weiss, R. (1997). Bayesian sample size calculations for hypothesis testing. Journal
of the Royal Statistical Society: Series D (The Statistician) 46 (2), 185–191.
Wickham, H. (2015). R packages: organize, test, document, and share your code. ”
O’Reilly Media, Inc.”.
Zhang, H. (2010). Bayesian Power Prior Analysis and Its Application to Operational
Risk and Rasch Model. ERIC.
101
CURRICULUM VITAE
Shan Xiao
EDUCATION
• Ph.D. in Biostatistics, Minor in Bioinformatics, Indiana University, Indianapo-
lis, IN, 2017
• M.S. in Applied Statistics, Purdue University, Indianapolis, IN, 2014
• M.S. in Epidemiology & Biostatistics, Southeast University, Nanjing, China,
2011
• B.S. in Applied Mathematics, Southeast University, Nanjing, China, 2008
WORKING EXPERIENCE
• Summer Intern, CDER/FDA, Silver Spring, MD, June 2016-Sep 2016
• Research Assistant, Department of Biostatistics, Indiana University School of
Medicine, Indianapolis, IN, July 2014-May 2016
SELECT PUBLICATIONS
• Huang, D.L., Xiao, S., Dang, Q.Y., Tsong, Y. (2017). Concentration-QTc
Modeling: A Simulation Study. Submitted.
• Zimet, G.D., Dixon, B.E., Xiao, S., Tu, W.Z., Kulkarni, A., Downs, S.M. (2017).
Effects of Automated Physician Reminders and Recommendation Scripts on
Initiation of HPV Vaccination. Submitted.
• Zimet, G.D., Dixon, B.E., Xiao, S., Tu, W.Z., Linday, B., Sheley, M.E., Dugan,
T., Church, A., Downs, S.M. (2017). Physician Computerized Decision-Support
Systems (CDSS) Prompts and Administration of 2nd and 3rd Doses of HPV
Vaccine: A Randomized Clinical Trial. Submitted.
• Stupiansky, N., Liau, A., Rosenberger, J., Rosenthal, S., Xiao, S., et al (2017).
Young Men’s Disclosure of Same Sex Behaviors to Health Care Providers and
the Impact on Health: Results from a U.S. National Sample of Young Men who
have Sex with Men. AIDS patient care and STDS. Accepted.
• Aalsma, M., Gilbert, A., Xiao, S., Rickert V. (2016). Parent and Adolescent
Barriers and Facilitators to Adolescent Preventive Health Care Utilization. The
Journal of pediatrics.169: 140-145
• Liu, P., Xiao, S., Shi, Z., et al (2011). Bayesian evaluation of the HIV anti-
body screening strategy of duplicate ELISA in Xuzhou blood center, China.
Transfusion. 51(4): 793–798.
• Liu, P., Yang, H., Qiang, L., Jin, H., Xiao, S., Shi, Z. (2010). Evaluation of 30
commercial assays for the detection of antibodies to HIV in China using classical
and Bayesian statistics. Journal of virological methods. 170(1): 73–79.
PRESENTATIONS
• A simulation study to evaluate the performance of different models in concentration-
QT analysis. Oral presentation at CDER/FDA, August 2016. Silver Spring,
MD.
